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Rheumatoid arthritis (RA) is an inflammatory disease characterized by synovitis, systemic 
inflammation, autoantibodies that causes joint damage, disability, decreased quality of life, 
and cardiovascular and other comorbidities. Its aetiology as well the exact etiopathogenetic 
mechanisms are not well clear so far. RA is triggered by an interplay between genes and 
environmental factors.  
Several studies showed that microorganisms play an important role in triggering 
autoimmunity through different mechanisms of action. Viral and bacterial infections, such as 
those caused by Epstein-Barr virus (EBV), Human Endogenous Retrovirus (HERVs) and 
mycobacteria, may play a pathogenetic role in RA through immunological cross-reactivity or 
molecular mimicry. Sardinians have a peculiar genetic background resulting from a long 
lasting geographical isolation with a strong incidence and prevalence of different 
autoimmune disease such as RA, multiple sclerosis (MS) and diabetes. 
During this PhD course, I have studied the role of EBV, HERV-K and Mycobacterium avium 
subsp. paratuberculosis (MAP) in RA pathogenesis and other rheumatic diseases for a 
better understanding of how these infectious agents can lead to a deregulation of 
transcription factors such as Interferon Regulatory Factor 5 (IRF5) that is important in the 
regulation of different cells type like macrophages and neutrophils.  
Finally, in order to better understand the etiopathogenesis of RA, an animal model has been 
used to study the molecular mechanisms involved in the above-mentioned diseases and to 
better understand the link between the environment and genes in RA with an objective to 
develop new therapeutic strategies. 
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L'artrite reumatoide (AR) è una malattia infiammatoria caratterizzata da sinovite, 
infiammazione sistemica, autoanticorpi che causano danni articolari, disabilità, patologie 
cardiovascolari comportando una diminuzione della qualità della vita. La sua eziologia e gli 
esatti meccanismi eziopatogenetici non sono ancora ben chiari. L'AR è innescata da 
un'interazione tra geni e fattori ambientali.  
Diversi studi hanno dimostrato che i microrganismi hanno un ruolo importante nell'innescare 
l'autoimmunità attraverso diversi meccanismi d'azione. Le infezioni virali e batteriche, come 
il virus di Epstein Barr (EBV), i Retrovirus Endogeni Umani (HERVs) ed i micobatteri, 
possono svolgere un ruolo patogenetico nell'AR attraverso la reattività crociata o il 
mimetismo molecolare. I sardi hanno uno sfondo geneticamente isolato con una forte 
incidenza e prevalenza di diverse malattie autoimmuni come l’AR, la sclerosi multipla (SM) 
e il diabete. 
Nel presente lavoro è stato analizzato il ruolo di EBV, HERV-K e Mycobacterium avium 
subsp. paratuberculosis (MAP) nella patogenesi della AR e di altre malattie reumatiche per 
capire come questi agenti infettivi possono portare alla deregolazione di fattori di trascrizione 
come l’Interferon Regulatory Factor 5 (IRF5), quest’ultimo implicato sia nella regolazione 
della maturazione che nella funzione di diversi tipi di cellule immunitarie come i macrofagi e 
neutrofili. 
Infine, al fine di comprendere meglio l'eziopatogenesi della AR, è stato utilizzato il modello 
animale perché rappresenta un buon modello per studiare i meccanismi molecolari coinvolti 
nelle malattie umane, per approfondire i legami tra ambiente e geni nell’artrite con l'obiettivo 
di sviluppare nuove strategie terapeutiche. 
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CHAPTER 1: Introduction 
Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that mainly affects 
diarthrodial joints. It can potentially involve every compartment in the organism such as skin, 
blood vessels, heart, lungs and muscles. At the level of the joint the inflammatory process 
has an erosive character and can lead to the destruction of the juxta-articular bony heads 
and to the ankylosis (Scott DL et al., 2010). 
RA was first described by Augustin-Jacob Landré-Beauvais in the early 1800s. The term 
“rheumatoid arthritis” was coined by Alfred Bering Garrod in 1876 and was definitively 
adopted at the American Rheumatism Association (ARA) in 1941. 
Epidemiology 
RA is the most common inflammatory arthritis, affecting from 0.5 to 1% of the general 
population worldwide. The prevalence ranges from 0.3 to 2% of the population, while yearly 
incidence is of 2-4 new cases per 10 000 inhabitants (Fig. 1). Females are predominantly 
affected with a male/female ratio of 1:4. The disease can occur at any age, but it generally 
occurs in subjects between 40 and 60 years old. In Italy, it was estimated that more than 5 
million people suffer from RA with a higher prevalence among women, and that about one 
fifth have the most disabling and severe forms. If RA is not properly diagnosed and controlled 
in time, the joints may become permanently deformed resulting in progressive limitation and 
loss of self-sufficiency that leads in turn to a worsened quality of life, loss of working capacity 
and high social and economic costs. 
Dr. Bo Marco – “Immune response against Mycobacterium avium subsp. paratuberculosis, 
Epstein-Barr virus, HERV-K and IRF5 in rheumatoid arthritis” – PhD thesis in Life Sciences and 




People per 100 000 with RA 
 
Fig. 1: Global prevalence of RA https://www.who.int/healthinfo/global_burden_disease/estimates_country/en/ 
 
Etiopathogenesis 
The etiology and pathogenesis of RA are complex and multifaceted. Although RA etiology 
remains unknown, different studies supported the hypothesis that the interaction of 
environmental and genetic factors is responsible (Scott DL et al., 2010), (Klareskog L et al., 
2009), (Feldmann M et al., 1996). The disease is characterized by an activation of the 
immune system which, through a complex series of events, involve both humoral and 
cellular immunity leading to the development of an acute inflammatory process and later to 
its maintenance and chronicity. As discussed later, this process implicates certain specific 
genes that can culminate in the breakage of immune tolerance and lead to autoreactivity.  
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From a genetic point of view, it has been pointed out that class II HLA-DR4 and DR1 
antigens are the ones that confer greater susceptibility to the disease. The initiation of RA 
probably begins years before the onset of clinical symptoms. The loss of tolerance leads to 
autoreactivity and this process is due to specific genes, including class II major 
histocompatibility complex (MHC) genes, protein tyrosine phoshatase-22 (PTPN22) 
(Begovich AB et al., 2004), and peptidylarginine deiminases. The first description of a 
genetic link between HLA-DR and RA has been described in the 1970 century. HLA-DR4 
was present in 70% of RA subjects and only 30% of healthy controls (HCs). Other HLA 
genes such as DRB*1301 that contain, in the third hypervariable region of DRβ-chains, the 
DERAA sequence, are associated with decreased susceptibility to RA (van der Woude D et 
al., 2010). 
In addition, signal transduction gene polymorphisms, cytokine promoter polymorphisms and 
population-specific genes (e.g., PADI4 in Koreans and Japanese) are involved. PTPN22 
and PADI4 increase the risk in some racial and ethnic groups, but not in all. It is likely that 
the earliest phases are characterized by repeated activation of innate immunity.  
A number of environmental factors clearly contribute to RA susceptibility, although no 
specific exposure has been identified as the pivotal agent. Smoking is the best defined 
environmental risk factor for RA and the interaction between HLA-DR and tobacco exposure 
is perhaps the best example of how genes and environment conspire to enhance the risk.  
Other triggering factors are represented by bacterial agents (E. coli, Streptococcus, 
mycoplasma and mycobacteria), viral agents (EBV, varicella zoster virus (VZV), rubella 
virus, Herpes Simplex, Parvovirus B19) and superantigens (Arleevskaya MI et al., 2016).  
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These agents can trigger joint inflammation with a direct and/or indirect mechanism. This 
process occurs often in normal people but is self-limited, while in subjects with a 
predetermined propensity for an immune hyper-reactivity or autoreactivity it could lead to a 
different outcome.  
The indirect mechanism is the most popular mechanism in which we may observe the 
triggering of a cross immune response between microbial antigens and articular auto-
antigens. In addition, environmental stresses can lead to post-transcriptional modifications 
of proteins in mucosal surfaces or the synovium, especially carbamylation or citrullination of 
arginine residues. People with a propensity for RA can develop antibodies (Abs) against 
these modified proteins with production of rheumatoid factors (RFs) and anti-citrullinated 
protein Abs (ACPAs). 
 
Pathological anatomy 
The most important alterations observed in RA patients are synovitis, nodules and 
rheumatoid vasculitis. Synovitis is initially characterized by exudation, cellular infiltration 
(lymphocytes and plasma cells) and proliferation (vessels, synoviocytes, fibroblasts). 
Proliferation is becoming increasingly important and leads to the formation of the synovial 
cloth that invades the subchondral bone and destroys the cartilage leading to ankylosis. The 
nodules are found in 15-30% of the cases, they can be superficial (skin, subcutaneous, 
tendinous sheaths) or deep (internal organs), single or multiple and their diameter varies 
from a few millimeters to 2 or more centimeters. Histologically they are characterized by a 
central zone of fibrinoid necrosis, an intermediate zone formed by one or more layers of 
cells arranged in a palisade and an external zone of granulation tissue infiltrated by 
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lymphocytes and plasma cells. Vasculitis is not specific, affects small vessels and can 
involve any organ. 
Diagnostic classification 
Different RA diagnostic classifications have been used during the years after the first 
description (Arnett FC et al., 1988), (Kasturi S et al., 2014). The most recent diagnostic 
classification is based on 2010 ACR/EULAR Classification Criteria for RA (criteria of the 
American College of Rheumatology) (Aletaha D et al., 2010).  
Therapy 
The therapy is multidisciplinary and consists of combining the pharmacological approach 
[NSAIDs (Nonsteroidal anti-inflammatory drugs), steroids, DMARDs (disease-modifying 
antirheumatic drugs), biological drugs] with non-pharmacological one (rehabilitation, 
surgical correction, psychological approach) (Pinals RS et al., 1981). The drugs used in RA 
are aimed at reducing inflammation and consequent structural damage. They are called 
disease-modifying antirheumatic drugs and can be classified into synthetic DMARDs and 
biological DMARDs. Synthetic DMARDs are also classified into conventional synthetic 
DMARDs and target synthetic DMARDs (Smolen JS et al., 2014). 
Biologic drugs, recently introduced for the treatment of RA, have been very successful; these 
are molecules (monoclonal antibodies), obtained using recombined DNA technology, which 
can selectively block a cytokine or a particular cellular interaction identified as key points in 
the pathogenesis of the disease. Biological drugs allowed clinical remission in a high 
percentage of patients and proved to slow down (in some cases and conditions blocked) the 
radiological progression of arthritis. Those currently on the market for RA have as molecular 
targets the tumor necrosis factor (TNF), the interleukin receptor 1, the IL-6 receptor, the CD-
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20, the CD-80 and the CD-86 (also known as B7-1 and B7-2, both of which are fundamental 
to the co-stimulation of B lymphocytes - T lymphocytes) (Nam JL et al., 2014). In Italy, 
Europe and USA, five anti-TNFα have been approved for the treatment of RA: Infliximab 
(originator, biosimilar), Etanercept (originator, biosimilar), Adalimumab, Golimumab and 
Certolizumab. All these drugs have been shown to be more effective on a clinical profile 
when administered together with methotrexate, especially in the inhibition of radiological 
damage (Maini RN et al., 1998). The biologicals with different mechanisms of action to date 
prescribed for the treatment of RA are: Abatacept, Tocilizumab, Anakinra and Rituximab 
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CHAPTER 2: Infectious agents and RA 
Human endogenous retrovirus-K 
For a long time, endogenous retroviruses (ERVs) and other repetitive elements have been 
considered as junk DNA having no impact on the host. However, over the years, it has been 
possible to discover the evolutionary interplay between ERVs and host biology, leading to 
interesting results. ERVs are viral elements that are part of the animal and human genome 
and that have probably originated from retroviruses. Today we know that ERVs constitute a 
quantitatively significant component of the human genome; it is estimated that there are 
roughly 98 000 sequences of complete ERVs and their fragments and that they represent 
approximately 8% of the whole human genome. If we add other retro elements such as 
retrotransposons (fragments of DNA that can be independently transcribed in an 
intermediate to RNA and consequently replicate in different positions of the genome), it is 
believed that more than 40% of the genome of an individual is of external origin. These 
sequences of endogenous elements inserted into the seminal line cells by retro-transcription 
mechanisms are inherited as stable mendelian genes (Temin HM., 1985). 
It seems that Human endogenous retrovirus-K (HERV-K) could has a role in the autoimmune 
process of RA in which the immune system fails to discriminate self from non-self. Several 
factors can contribute to the phenomenon of molecular mimicry, such as genetic 
predisposition (HLA genes), environmental factors, age and sex (Freimanis G et al., 2010). 
In RA, it was pointed out that HERV-K-10 has amino acid sequences homologous to IgG1Fc, 
a target of rheumatoid factor. In patients with RA, it has been observed that there is a 
differential expression of the HERV-K (HML-2) genes and the transcription of Rec proteins. 
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Furthermore, it was observed that in the mononuclear cells of synovial fluid of RA patients 
there is a high expression of the HERV-K type 1 virus encoding a super antigen capable of 
stimulating a high number of reactive T lymphocytes (Tugnet N et al., 2013). The immune 
response against HERV-K is guided by an antigen and could be an initial event in the 
autoimmune mechanism that leads to the loss of tolerance to the organism's own antigens. 
A connection is therefore possible between the activation of HERV-K and the inflammatory 
process. Moreover, it was observed that in patients with RA there is a statistically significant 
association between the viral load of HERV-K1 in the plasma and the activity of the disease. 
This association could reflect the increased cellular activation found in peripheral blood 
during the period of active disease which, in turn, can facilitate the activation and perhaps 
the replication of HERV-K type 1 followed by a high viral load (Tugnet N et al., 2013). This 
association has been highlighted only with HERV-K type 1, which encodes the Np9 
oncoprotein. In fact, RA is characterized by a chronic inflammation and an incorrect 
proliferation of invasive synoviocytes, such as the growth of cancer cells. This could suggest 
that the activation of HERV-K 1 could contribute to the chronicity of the process, where the 
synoviocytes show defects in apoptosis. 
Finally, the differential activation and expression of HERV-K could be induced by 
environmental signals or by the activation of the immune system following exposure to 
triggering factors that may include exogenous viruses such as EBV, also involved in RA 
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Epstein-Barr virus (EBV), known as human gammaherpesvirus 4, is one of the most 
common viruses in humans identified by Anthony Epstein and Yvonne Barr in 1964 using 
electron microscopy in biopsies of Burkitt’s Lymphoma (BL). The virus belongs to the 
Herpesviridae family, gammaherpesvirinae subfamily and genus Lymphocryptovirus. EBV 
is an ubiquitous virus and 90% of the worldwide population is infected. The virus is orally 
transmitted and infects epithelial cells of the oropharynx (Young LS et al., 2004).  
EBV is about 122-180 nm in diameter and is composed of a linear, double helix of DNA 
which contains ~172.000 base pairs and 85 genes that codifies for more than 85 proteins. 
There are six nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C and EBNA-LP); three latent 
membrane proteins (LMPs 1, 2A, 2B); small non-polyadenylated RNAs, EBERs 1 and 2; 
microRNAs (miR-BHRF1 and miR-BART); and several early lytic genes (Young LS et al., 
2004). 
Deoxyribonucleic acid is enclosed within a protein nucleocapsid, which is surrounded by a 
tegument made of protein, in turn surrounded by an envelope containing both lipids and 
surface projections of glycoproteins, which are essential to infect the host cell. EBV is 
usually found in the episomal form inside cells, although, in some cases it has been 
described as a viral DNA randomly integrating into the host’s genome (Young LS et al., 
2004). Also, EBV has the ability to express different viral proteins according to different cells 
and differentiation stages of infected cells. 
EBV is involved in several diseases, e.g. infectious mononucleosis (IM), BL, Hodgkin’s 
lymphoma, gastric cancer, nasopharyngeal carcinoma and other neoplasms. Recent 
reports show that EBV has been associated with autoimmune disease including multiple 
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sclerosis (MS), systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) and RA 
(Olsson T et al., 2017), (Ascherio A et al., 2015), (Trier NH et al., 2019). 
Mycobacterium avium subspecies paratuberculosis 
Mycobacterium avium subspecies paratuberculosis (MAP) belongs to the order of the 
Actinomycetales and is part of the group Mycobacterium avium complex (Mac) (Harris NB 
et al., 2001). MAP is an optional anaerobic Gram-positive intracellular bacterium, with a 
small rod shape, ranging from 0.15μm to 1.15μm (Fig. 2). It is strongly acid-alcohol resistant, 
asporiginal and capsule-free bacterium (Harris NB et al., 2001), (Lévy-Frébault VV et al., 
1992).  
 
Fig. 2. Mycobacterium avium subspecies paratuberculosis https://johnes.org/ 
It is a mandatory pathogen for ruminants that requires the presence of a favorable 
environment to multiply. MAP has a considerable tropism towards ruminant animal tissue 
and is the etiologic agent of severe gastroenteritis in ruminants known as Johne’s disease 
or paratuberculosis (Chiodini RJ et al., 1984), but other animal can be also affected. Recent 
research on a survey of 48 countries found paratuberculosis to be very common in livestock 
representing also a serious problem for public health (Whittington R et al., 2019), (Garvey 
M., 2018). 
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It is a bacterium that grows very slowly in culture media taking up to 6-8 weeks at 37°C for 
a visible growth, with duplication times of about 48-72 hours compared to 12-24 hours of 
Mycobacterium tuberculosis. This feature is mostly due to the bacterial wall rich in complex 
lipids that slows metabolic exchange with the external environment. 
MAP may occur in two forms: bacillary or spheroplasty. The presence of a large number of 
bacteria in a bacillary form is necessary to give rise to overt disease (pluribacillary form) and 
can be detected with the coloring of Ziehl-Neelsen. Few bacteria in spheroplastic form, on 
the other hand, are able to cause the disease (paucibacillary form, characterized by the 
formation of granulomas) (Chiodini RJ et al., 1984). 
MAP is transmitted via the orofecal route and is localized in the intestine of the host, it is 
excreted with the stool of the infected animals, it is able to withstand exposure to the 
environment for a long time, enhancing the risk for the cycles of re-infection and making it 
difficult to eradicate the disease in endemic areas. The presence of MAP in the environment 
is influenced by the type of soil, pH and soil moisture, however this microorganism tolerates 
a wide range of temperature excursions. Through rainwater, MAP can be transferred to 
waterways, such as lakes and rivers, and some controls have documented its presence in 
these types of water (Chiodini RJ et al., 1984), (Richardson H et al., 2019). The water 
intended for domestic use is subjected to various treatments that make it possible to 
eliminate the solids suspended in it and reduce the probable presence of MAP; however, its 
complete elimination is difficult due to the high resistance to chlorine and other biocides, 
which constitutes a danger of contamination for domestic supplies (Whan LB et al., 2001). 
In all hosts, the most common route of infection is represented by the ingestion of feces or 
contaminated foods such as milk, colostrum or water. Once penetrated into the host, MAP 
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reaches the intestine, where, through transcytosis, it passes through the membrane of the 
M cells in the Peyer plaques (besides being able to infect the epithelial cells of the mucosa) 
and into the deep layer of the intestinal mucosa, where it is captured by macrophages. MAP 
has a marked capacity to resist the enzymatic degradation mechanisms implemented by 
macrophages during infection; this ability allows MAP not only to survive, but also to grow 
and multiply, albeit very slowly, within these cells. The mechanism by which the 
mycobacterium survives and multiplies inside the phagosome is still not clear. Phagosomes 
constitute an extremely hostile environment to many bacteria due to the rather acid pH, the 
presence of proteolytic enzymes and different antibacterial molecules such as defensins 
and toxic intermediates of oxygen and nitrogen. It is probable that MAP inhibits the action of 
oxygen and nitroxide by the synthesis of oxidase and alkyl hydroperoxidase C and D. It is 
also known that, in the case of mycobacterial infections, normal phagosome-lysosome 
fusion does not occur with subsequent acidification and the release of hydrolytic enzymes. 
Recent studies have shown that the components of the host cell, steroid cholesterol and a 
surface phagosomal protein called TACO (tryptophane aspartate-containing), promote the 
establishment of intracellular infection by mycobacteria (Pieters J et al., 2002), (Meena LS 
et al., 2010). During growth within the macrophage phagosome, mycobacteria develop a 
capsule similar to a lamellar lining. The presence of MAP also induces a significant increase 
in the expression of pro-inflammatory cytokines in the macrophage, such as IL-1α 
(interleukin-1α), IL-1, IL-6, IL-12 and TNF-α. The latter, together with IL-12, stimulates the 
natural killer (NK) lymphocytes to produce INF-γ, in turn responsible for the activation of 
other macrophages which accentuate the inflammatory process (Chiodini RJ et al., 1984). 
This bacterium has been also associated to Crohn’s disease (McNees AL et al., 2015), 
(Kuenstner JT et al., 2017), (Feller M et al., 2007), (Sechi LA et al., 2005). The possible 
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involvement of MAP has been suggested for the first time in 1984 by Rodrick Chiodini by 
the close similarity from a clinical, pathological and epidemiological point of view, between 
Crohn's disease and Johne's disease of ruminants (Chiodini RJ 1984). Another proof was 
the first isolation of MAP from a Crohn's patient with a further successful cultivation (Chiodini 
RJ et al., 1986). 
Following colonisation of the host, the parasitic organism alters the host immune system 
through molecular mimicry, displaying peptide sequences similar to that of the host cells and 
causing a disruption of self vs. non-self-recognition. Theoretically, the failure to recognize 
the invading organism from host cells may result in numerous autoimmune conditions. 
In addition to Crohn’s disease, several studies show that MAP could be another triggering 
factor in other human autoimmune diseases such as MS (Frau J et al., 2013), (Cocco E et 
al., 2011) (Bo M et all., 2018b), Type 1 Diabetes (T1D) (Songini M et al., 2010) and 
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Aim of the study 
The goals of my research can be summarized in the following points: 
 Deepening knowledge on the role of endogenous retroviruses in RA disease. 
 Analysis of the synergistic effect between EBV, HERV-K and MAP in RA disease. 
 Investigation of the molecular mimicry mechanism between EBV, MAP and host 
peptides.  
 Starting from previous discoveries of anti-Interleukin-2 (IL-2) Abs present in subjects 
affected by autoimmune diseases and their possible role in alterations involving 
regulatory T cell responses, I investigated the immune response against two epitopes 
of IL-2 in RA Sardinian patients. 
 Analysis of reactivity to PtpA and PknG proteins secreted by MAP in the sera of RA 
patients and correlation analysis with immune response against BOLF1, MAP_4027 
and IRF5 peptides.  
 Investigation of the correlation between humoral reactivity against MAP and serum 
lipoprotein levels in subjects at T1D risk (rT1D) grouped by geographical background 
and in patients affected by MS and RA. 
 Considering that anti-CCP antibodies are a biomarker for precocious diagnosis of RA, 
I’ve investigated the reactivity against wild type and citrullinated peptides of MAP, 
EBV and IRF5 in RA, SLE, systemic sclerosis (SSc) and SS patients in order to 
assess similitudes and/or differences. 
 Investigation of the reactivity against three homologous peptides IRF5, BOLF1 and 
MAP previously analyzed in human, in the serum of three arthritis models (AIA, 
Collagen-Induced Arthritis (CIA) and Collagen Antibody-Induced Arthritis (CAIA)) and 
comparison with human results. 
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CHAPTER 3: Mouse model of rheumatoid arthritis 
RA is an autoimmune/inflammatory disease that causes joint damage, disability, decreased 
quality of life, and cardiovascular and other comorbidities. The etiology is unknown and 
pathogenesis is not clear yet. For this reason, in order to better understand the complexity 
of the pathogenesis of RA, animal models have been extensively used to understand the 
molecular mechanisms involved in human diseases with the objective to develop new 
therapeutic strategies. Obviously, a disease identical to RA cannot be developed in 
experimental animals because they are different species with different genetics and life 
environments, as compared with humans.  
Many rodent models of arthritis have been developed through the decades of research in 
the field and, among all animal models, mouse models of RA have many features of human 
disease. This has contributed to numerous advances to better understand pathogenic 
pathways in RA and major advances in development of new drugs (Bevaart L et al., 2010), 
(McNamee K et al., 2015), (Kollias G et al., 2011). This way, by translating results from 
mouse to human, it has been possible to refine the understanding of molecular pathways 
involved in disease pathogenesis. These outcomes have been achieved by combining 
knowledge on RA-associated genes, environmental factors and the presence of serological 
elements. 
Arthritis models can be induced in different ways that can be divided into 3 groups:  
1) those elicited by active immunization,  
2) those elicited by passive immunization, 
3) those elicited by the administration of irritant chemicals resulting in chronic 
inflammation. CIA is an example of an active immunization strategy, whereas 
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antibody- induced arthritis models, such as collagen antibody–induced arthritis and 
K/BxN antibody transfer arthritis, represent examples of passive immunization 
strategies (Caplazi P et al., 2015), (Asquith DL et al., 2009). 
Induced arthritis models 
RA is characterized by immune perturbation in both the innate and adaptive compartments 
and subsequent chronic inflammation. The etiology is complex and, for this reason, it was 
indispensable to generate animal models that better represent RA disease for a simplified 
study of RA immunopathogenesis. 
Collagen-induced arthritis 
CIA is one of the models used. Arthritis is normally induced in mice by immunization with 
autologous or heterologous type II collagen in adjuvant. Susceptibility to collagen-induced 
arthritis is strongly associated with major histocompatibility complex class II genes, and the 
immunopathogenesis of CIA involved both a T-cell and B-cell specific response to type II 
collagen. The chief pathological features of CIA include a proliferative synovitis with 
infiltration of polymorphonuclear and mononuclear cells, pannus formation, cartilage 
degradation, erosion of bone, and fibrosis (Brand DD et al., 2007). As in RA, pro-
inflammatory cytokines, such as tumour necrosis factor α (TNFα) and interleukin (IL)-1β, are 
abundantly expressed in the arthritic joints of mice with CIA, and blockade of these 
molecules results in a reduction of disease severity. 
Antigen-induced arthritis  
The above indicated model of arthritis can be developed when mice are primed with an 
antigen like methylated bovine serum albumin (mBSA) in complete Freund’s adjuvant (CFA), 
and subsequently challenged by intra-articular injection of the same antigen (Asquith DL et 
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al., 2009). Such models are useful in that mice of several strains can be investigated to 
establish a hierarchical role for given factors in adaptive immune-mediated articular damage. 
Subsequent pathology comprises immune complex-mediated inflammation with infiltration 
of polymorphonuclear cells, pannus formation, erosion of cartilage and bone, followed by 
articular T-cell-mediated responses and in particular is Th17 dependent (Asquith DL et al., 
2009), (Egan PJ et al., 2008).  Also, regarding the molecular pathway of immune response, 
a recent study has shown that synovial macrophages from the AIA joint have high levels of 
IRF5 that is an important transcription factor implicated in the adjustment of immune 
response, both innate and adaptive (Weiss M et al., 2013). Through the comparison of naïve 
joints and arthritis inflammed joints, researchers have shown that IRF5 deficient mice (IRF5-
/-) had a significantly less swelling at day 2 in comparison with wild-type controls (WT). 
Reduced swelling corresponded to a decreased number of cells recovered from excised 
knee joints at that point. Also, IRF5 knockout mice showed a significantly lower synovial 
membrane thickening score in the mBSA-challenged knees than WT mice and reduced 
synovial membrane thickening has also been observed at day 7 (Weiss M et al., 2013). 
Macrophages and neutrophils are the two major types of myeloid cells involved in RA 
inflammatory process. Considered the heterogeneity of macrophages (Murray PJ et al., 
2014), (Sieweke MH et al., 2013) and the interesting role of neutrophils able to form distinct 
subsets and extracellular traps (NETs) (Khandpur R et al., 2013), a variety of destructive 
enzymes as well as autoantigens can be generated (Becher B et al., 2014), (Ericson JA et 
al., 2014). Further investigations must be carried out to understand the exact nature of the 
myeloid cells in various inflammatory diseases; this not only will provide other clues about 
pathogenesis, but can also contribute to the discovery of more effective therapeutics 
improving the quality of life of RA subjects. 
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In this research AIA mouse model has been used to analyse the immune response against 
viral and bacterial epitopes in order to better understand the possible role of some infections 
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CHAPTER 4: Investigating the role of viral and bacterial infections in RA and other 
rheumatic diseases 
*** 
Identification of a HERV-K env surface peptide highly recognized in rheumatoid 
arthritis (RA) patients: a cross-sectional case-control study 
Among environmental factors, the role of viruses in autoimmunity has been long postulated 
and endogenous retrovirus (HERV) is one potential candidate. 
The hypothesis of a potential pathogenic link between HERV‐K and RA is based on several 
observations descending from both polymerase chain reaction (PCR)‐based and serological 
studies (Trela M et al., 2016). The prevalence of insertionally polymorphic HERV‐K was 
reported increased significantly in the RA population (Krzysztalowska-Wawrzyniak M et al., 
2011). Moreover, a significantly increased expression of HERV‐K genes and transcription 
of viral proteins has been demonstrated in peripheral blood, synovial fluid and synoviocytes 
of RA patients compared to HCs (Hohn O et al., 2013), (Reynier F et al., 2009). In addition, 
common amino acid sequences between HERV‐K and host antigens have been reported in 
RA, suggesting that a mechanism of molecular mimicry may play a role in disease 
pathogenesis (Freimanis G et al., 2010), (Nelson PN et al., 2014). 
Considering this background, we performed an in silico analysis to predict key antigenic 
regions of HERV‐K on the basis of their putative ability in igniting an RA‐specific humoral 
response. Candidate epitopes were then synthesized as short peptides, and an enzyme‐
linked immunosorbent assay (ELISA) was used to test the reactivity of RA and control serum 
to HERV‐K peptides. In silico analysis performed using IEDB Analysis Resource software, 
in particular the Antibody Epitope Prediction, Bepipred linear epitope prediction software 
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(http://www.iedb.org/home_v3.php), allowed us to identify different antigenic peptides 
derived from HERV‐K env surface protein (UniProtKB Accession number: Q69384). 
Four peptides were selected for further analysis: 
▪ HERV‐K env19–37 (VWVPGPTDDRCPAKPEEEG) 
▪ HERV‐K env109–126(RPKGKTCPKEIPKGSKNT) 
▪ ERV‐K env164–186 (SGQTQSCPSAQVSPAVDSDLTES) 
▪ HERV‐K env205–226 (EKGISTPRPKIISPVSGPEHPE) 
Results 
Antibodies against HERV‐K env peptides were tested in serum of 70 RA patients and 71 
HCs. HERV‐K env‐su19–37 antibodies were above positivity in the sera of 19% RA patients 
and in only 3% of HCs (AUC=0.84, RA versus HCs p<0.0025) (Fig. 3a). 
Regarding HERV‐K env‐su109–126 peptide, 9% of RA patients and 3% of HCs were positive 
for antibodies in serum (p=0.165, AUC=0.71) (Fig. 3b). 
No statistical differences were found regarding positivity against HERV‐K env‐su164–186 in 
RA patients (3%) versus HCs (3%) (AUC=0.56, Fig. 3c). HERV‐K env‐su205–226 peptide was 
recognized in the sera of 6% of RA patients and 3% of HCs (p=0.44, AUC=0.75) (Fig. 3d). 
No significant difference was found in the proportion of HERV‐K env‐su19–37 antibody 
positivity according to disease activity (moderate–severe RA versus low activity and 
remission RA) and type of immunosuppressive treatment.  
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Fig. 3. Prevalence of Abs against peptides derived from HERV‐K envelope (env) protein. 
Scatterplots present median values with interquartile range. Area under receiver‐operating 
characteristic (ROC) curve (AUC) as well as significant P‐values are displayed. 
 
Mameli G et al. Clinical & Experimental Immunology, 2017 
No correlation was found between HERV‐K env‐su19–37, antibody levels and RA descriptors 
[age, DAS‐28, HAQ, C‐reactive protein (CRP) and erythrocyte sedimentation rate (ESR)]. 
The same results were obtained with the other HERV‐K env‐su peptides tested (data not 
shown). 
Discussion 
HERV‐K mRNA transcripts and IgG anti‐HERV‐K Abs have been associated with 
autoimmunity and cancers, as well as neurological conditions (e.g. MS) and rheumatic 
diseases (Manghera M et al., 2016), (Balada E et al., 2010), (Tugnet N et al., 2013). 
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For the first time, a humoral response against selected surface epitopes of HERV‐K env‐su 
(HERV‐K env‐su19–37, HERV‐K env‐su109–126 and HERV‐K env‐su209–226) was searched in 
patients with RA and controls. Among them, the most interesting peptide was HERV‐K env‐
su19–37, which was recognized in the sera of 19% of RA patients and in only 3% of controls. 
HERV‐K env‐su19–37 has a high homology with different human antigens, including myosin 
(with 61% of positive amino acids with sequence EAW76415.1) and netrin (73% of positive 
amino acids with sequence NP_006172.1). Evidence of a molecular mimicry as a 
pathogenic mechanism linking HERV‐K to RA was provided by several groups. Freimanis 
and co‐authors (Freimanis G et al., 2010) demonstrated a significant humoral response in 
RA patients against one HERV‐K epitope which shares residues with collagen type II, a 
common target of pathogenic RA autoantibodies. Similarly, IgGs against antigenic peptide 
on the matrix segment of HERV‐K10 sharing common sequence with IgG1Fc, a target of 
rheumatoid factor, were demonstrated in RA patients (Nelson PN et al., 2014). An intriguing 
explanation of this result would be that the surface epitope HERV‐K env‐su19–37 may function 
as an ‘autoantigen’ driving a secondary immunological response. 
Unfortunately, it was not possible to find any statistically significant correlation between 
antibody positivity and disease activity, systemic inflammation and type of 
immunosuppressive treatment. It may be possible that therapy could alter the humoral 
response. Notably, also in the series of RA patients described by Nelson and co‐authors, 
levels of antibodies to HERV‐K antigens showed no correlation with RA disease 
activity (Nelson PN et al., 2014). 
However, it should be remembered that a number of conditions, both genetic and 
environmental, may modulate HERV‐K env protein transcription contributing to changes in 
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the amount of immunological response. HERV‐K transcription exhibits a significant increase 
in the presence of proinflammatory cytokines [tumour necrosis factor (TNF)‐α and interleukin 
(IL)‐6] in RA with regard to the general population (Freimanis G et al., 2010). Exogenous 
viruses such as EBV, reported to be linked to RA (Erre GL et al., 2015), may transactivate 
and stimulate HERV‐K expression (Nelson PN et al., 2003). Moreover, differential HERV‐K 
transcription has been shown to be regulated epigenetically by the degree of DNA 
methylation in RA (Neidhart M et al., 2000). 
In conclusion, a specific humoral response against a superficial envelope epitope of HERV‐
K was demonstrated in RA patients. Results of this study clearly add to the evidence for a 
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Interferon regulatory factor 5 is a potential target of autoimmune response triggered 
by Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis in 
rheumatoid arthritis: investigating a mechanism of molecular mimicry 
As discussed above, 50% of the risk for RA is attributable to environmental contributors such 
as microbial infections (Duarte JH., 2015). EBV and mycobacteria were among pathogens 
reported to be involved in RA pathogenesis (Song YW et al., 2010), (Adtani P et al., 2015) 
(Ball RJ et al., 2015), (Erre GL et al., 2015), (Westergaard MW et al., 2015), (Rao DA et al., 
2017). 
In recent years, the potential role of IRF5 in the pathogenesis of RA has been frequently 
reported (Adtani P et al., 2015), (Eames HL et al., 2016), (Negi VS et al., 2014). IRF5 is a 
key transcription factor of the immune system, playing an important role in modulating 
inflammatory immune responses in many cell types including dendritic cells and 
macrophages by driving them toward a proinflammatory phenotype in concert with cytokines 
and chemokines expression, and by regulating B cell maturity and antibody production 
(Popko K et al., 2015), (Lino AC et al., 2016), (Dekkers J et al., 2016), (Olalekan SA et al., 
2015), (Fillatreau et al., 2015), (Mahabadi M et al., 2016). 
Recent in vivo studies identified the importance of IRF5 as a new link between the 
pathogenic activation of RNA-sensing Toll-like receptors and proinflammatory cytokine 
production in inflamed joints of arthritic mice (Duffau P et al., 2015). 
Intriguingly, the presence of a specific seroreactivity against EBV and MAP epitopes cross-
reacting with homologous human antigens such as IRF5 have been recently demonstrated 
in various autoimmune diseases (Cossu D et al., 2015), (Mameli G et al., 2015). Here it was 
supposed that significantly increased antibody titers following infection with MAP and EBV 
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may cross-react with homologous peptides of the transcription factor IRF5 leading to 
modulation of its expression. 
Based on the above-mentioned preliminary findings, our study aimed at evaluating the 
presence of a cross-reactivity between three homologous peptides derived from EBV 
tegument protein BOLF1 (BOLF1305-320), the MAP_4027 antigen (MAP_402718-32) (Eames 
HL et al., 2016), (Negi VS et al., 2014) and the human interferon regulatory factor 5 (IRF5424-
434) in a group of RA patients and HCs. 
Results 
71 RA patients (11 males, 60 females; median age 56.18) and 60 HCs (23 males, 37 
females; median age 46.1) were enrolled in the study; demographic and clinical features of 
RA patients and HCs are summarized in the Table 1. 
Table 1. Demographic, clinical and laboratory features of RA patients and HCs. 
 
Non normally distributed data are expressed as median (IQR). Health Assessment Questionnaire 
(HAQ); Disease Activity Score-28 (DAS-28); C-reactive protein (CRP); Erythrocyte sedimentation 
rate (ESR); Disease modifying anti-rheumatic drugs (DMARDs); Anti-Tumor Necrosis Factor alpha 
(Anti-TNF). 
Bo M et al. Clinical and Experimental Rheumatology, 2018 
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IRF5424-434 was found to have the highest Abs seroreactivity among the selected antigens 
being positive in 49 out of 71 RA patients (69%) and only in 5 out of 60 HCs (8%; AUC=0.9; 
p<0.0001; Fig. 4A and Fig. 4D). 
Abs against BOLF1305-320 were observed in 41 out of 71 RA patients (58%) and in 5 out of 
60 HCs (8%; AUC=0.9; p<0.0001; Fig. 4B and Fig. 4D). Humoral responses against 
MAP_402718-32 was detectable in 12 out of 71 RA patients (17%), whereas HCs showed Abs 
prevalence accounting for only 5% giving a p value close to the threshold of statistical 
significance (AUC= 0.6; p=0.051; Fig. 4C and Fig. 4D). 
Globally, RA subjects displayed much more increased positivity to at least one of the 
assessed epitopes compared to HCs with a high degree of statistical significance (71% vs. 
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Fig. 4: A-C) ELISA-based analysis of Abs reactivity against the homologous epitopes derived 
from human, EBV and MAP in RA patients and HCs. The sera were tested against plate-coated 
IRF5424-434 (A), BOLF1305-320 (B) and MAP_402718-32 (C) peptides. Bars represent the median ± 
interquartile range. Cutoff values for Abs positivity are indicated by dashed lines. P-values, 
respective to each epitope showed a statistical difference between RA patients and HCs and are 
reported above the distributions. D) Prevalence of Abs directed against BOLF1305-320, 
MAP_402718-32 and IRF5424-434 epitopes in RA patients and HCs. Total percentage of Abs positivity 
to at least one peptide is represented by the first bar in each group. Other bars correspond to a 
single-peptide positivity relative to each epitope. E) Peptides alignment obtained using Clustal 
W2. The results show the region of identity with a star (*), strong similar amino acid with a dot (.) and 
a missing region in dashes (-).  
 
 
Bo M et al. Clinical and Experimental Rheumatology, 2018 
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A good correlation was found for all the homologous pairs with the highest coefficient 
observed for BOLF1305-320 and IRF5424-434 peptides (R2=0.68; Fig. 5A) and slightly lower for 
BOLF1305-320 and its MAP_402718-32 homolog (R2=0.66; Fig. 5B). MAP_402718-32 and the 
human-derived IRF5424-434 peptides correlated to a somewhat lower extent than those 
described, however it still permitted us to hypothesize a cross-reactivity between the two 
epitopes (R2=0.61; Fig. 5C).  
To further demonstrate the presence of a cross-reactivity between MAP/EBV and self 
epitopes, ELISA-based competitive inhibition assays have been performed selecting 
IRF5424–434 as antigen representative of the highest Abs responses induced in RA 
patients. Of the three inhibiting concentrations tested, incubation with 10μg/ml peptide 
solution yielded the most accurate results with the lowest variability among replicates. The 
low OD values obtained for sera of two RA patients (RA22 and RA40) pre-incubated with 
BOLF1 and MAP_4027 peptides indicate that binding of Abs specific for the plate-coated 
IRF5424–434 was efficiently inhibited by its homologs (Fig. 5D). Most likely anti-BOLF1 and 
anti-MAP_4027 Abs are cross-reactive and target the same IRF5 conformational epitope. 
Moreover, the double IRF5-BOLF1 positivity pattern clearly visible among RA patients was 
changed in HCs that displayed a case of reactivity to IRF5-MAP_4027 and a single Abs 
response against MAP (Fig. 5E). 
When Fisher’s exact test was repeated excluding the two HCs with single and double anti-
MAP positivity, statistical significance relative to MAP_4027 greatly improved (p<0.0061). 
This picture may indicate the presence of Abs specific for the extracellular MAP 
phenotype that entered in contact with the HCs not MAP susceptible host conferring a 
natural protection against mycobacterial infection. On the other hand, a higher efficiency 
of the MAP-derived antigen to inhibit binding of anti-IRF5 Abs coupled with a simultaneous 
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reactivity to the other two homologous epitopes in cases with the triple-peptide positivity 
may be indicative of the synergistic role attributed to EBV and MAP in RA. 
Analysis of correlation between RA features and positivity of Abs demonstrated a close 
link between Abs and the burden of systemic inflammation. In particular multivariate 
regression analysis show that levels of CRP are the main predictors of high levels of Abs 
against BOLF1305-320 and IRF5424-434. 
Fig. 5: A-C) Scatter plot showing correlations between Abs titers recognizing (A) BOLF1305-320 
and IRF5424-434, (B) BOLF1305-320 and MAP_402718-32 and (C) MAP_402718-32 and IRF5424-434 in 71 RA 
patients. Person’s correlation was calculated through Graphpad Prism 6.0 software. D) Competitive 
inhibition assay in IRF5-coated ELISA plate. Sera of two RA patients were selected randomly 
among subjects highly positive for Abs against the three homologous epitopes. Bars indicate OD 
levels relative to the sera pre-incubated with single peptides or with no peptide. E) Coincidence of 
seroreactivity to the homologous peptides among Abs-positive RA and HCs subjects.  
 
Bo M et al. Clinical and Experimental Rheumatology, 2018 
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The currently accepted theory of RA pathogenesis assigns the main role in autoimmune 
reactions to different viral or bacterial infections leading to joint inflammation and chronic 
anatomical damage (Arleevskaya MI et al., 2016). Although activation of the T-cell response 
has a crucial role in RA pathogenesis, the B-cell response is equally responsible for the 
development of the disease due to the enhanced synthesis of immunoglobulins, usually 
IgGs (Rao DA et al., 2017). 
Within pathogenetic hypothesis, the theory of the "molecular mimicry" is based on amino 
acid sequence or structural motif homology between microbial epitopes and self proteins: 
due to this homology the immune response against microbial epitopes could also induce 
undesired humoral and/or cellular immunity against host proteins. 
Data from our study demonstrated a remarkable reactivity of RA sera against IRF5 
supporting the potential role of IRF5 as an important target in RA specific autoimmunity. 
Moreover, we also demonstrated a high grade of cross-reactivity between IRF5, EBV and 
MAP epitopes. 
A possible explanation for these results could be that in RA patients past EBV and/or MAP 
infection may induce specific humoral immunity reacting against IRF5 host protein. This 
secondary response may contribute, through the epitope-spreading phenomenon, to 
synovial tissue destruction with the production of Abs against previously “sequestered” 
antigens and amplification of autoimmune cascade. 
Study of genome-wide analysis demonstrated association between IRF5 polymorphisms 
and anti-CCP negative RA (Dieguez-Gonzalez R et al., 2008), (Stahl EA et al., 2010) 
suggesting that RA associated IRF5 polymorphism may lead to higher level of IRF5 
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expression by promoting stability of IRF5 messenger RNA. In addition, it has been recently 
demonstrated that IRF5 may act as a crucial mediator of joint inflammation, through Toll-like 
receptors signals activation in synovial macrophages cells promoting a vicious loop of 
proinflammatory cytokine and chemokine production and release in articular 
microenvironment (Duffau P et al., 2015). 
In this scenario, the cross-reactivity mounted against IRF5424–434, BOLF1305–320 and 
MAP_402718–32 may alter the function of the IRF5 protein, modulating or inhibiting its activity. 
Penetration of Abs into cell cytosol by endocytosis, a mechanism that has been 
demonstrated in some cells (Geis C et al., 2010), (Magrys A et al., 2007) may "regulate" 
IRF5 expression in a pro-inflammatory manner. The presence of a strong correlation 
between CRP levels and Abs titer in our series of patients further supports the hypothesis 
that autoantibodies against IRF5 may increase TLR-regulated production of pro-
inflammatory cytokine boosting systemic and local inflammation in RA. Shortcomings of the 
present study were mainly related to small sample size and a cross-sectional design 
including RA patients under immunosuppressive and anti-inflammatory treatment at the 
moment of study enrollment. 
In conclusion, this data suggests for the first time that IRF5 may be a target of the immune 
response in RA. Moreover, molecular mimicry involving EBV and MAP is proposed as a 
potential mechanism of anti-IRF5 autoimmune response. While association between anti-
IRF5 autoantibodies and RA is strongly significant, the functional capacity of these Abs to 
modulate IRF5 activity remains to be assessed.  
Further analysis of T cell responses will provide additional indices on cross-reactivity 
between BOLF1, MAP and IRF5 epitopes in a similar fashion to previously described EBV 
gp110 and E. coli dnaJ (Toussirot E et al., 2000), (Albani S et al., 1992). 
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Rheumatoid arthritis patient antibodies highly recognize IL-2 in the immune 
response pathway involving IRF5 and EBV antigens 
Results 
IRF5 is known to mediate virus-induced immune responses including expression of 
proinflammatory cytokines and its pro-apoptotic effect is activated by EBV in transformed 
cells (Xu D et al., 2011), (Cham CM et al., 2012). In SLE, IRF5 was found to negatively 
regulate the expression of IL-2 (Guo Q et al., 2016). IL-2 is crucial for function, expansion 
and survival of regulatory T cells (Treg) and balance within this pathway is disrupted in 
Th1-mediated autoimmune diseases such as RA, SLE or T1D (Bayer AL et al., 2005), 
(Thornton AM et al., 2004), (Niu Q et al., 2012). Recently, the loss of self-tolerance to IL-
2 has been described in T1D subjects whose peripheral blood mononuclear cells yielded 
high quantities of INF-γ upon stimulation with IL-2-derived peptides (Pérol L et al., 2016). 
Similarly, RA patients displayed raised levels of anti-IL-2 Abs supposed to affect IL-2 
bioavailability necessary for Treg homeostasis. 
In the present study, humoral responses to synthetic IL-2 peptides have been evaluated 
in a larger cohort of Sardinian RA patients. A correlation analysis with seroreactivity to 
HERV-K and homologous EBV, MAP and IRF5 epitopes permitted to assess a possible 
cross-reactivity of the antigens supposedly involved in RA pathogenesis. 
Human autoantigens along with EBV elicited the highest responses, while the strongest 
correlation was found between IL-2 and HERV-K pointing at a potential pathway that links 
EBV-induced transactivation of retroviral proteins and the subsequent cytokine secretion 
mediated by IRF5. 
Dr. Bo Marco – “Immune response against Mycobacterium avium subsp. paratuberculosis, 
Epstein-Barr virus, HERV-K and IRF5 in rheumatoid arthritis” – PhD thesis in Life Sciences and 
Biotechnologies – University of Sassari, Italy 
50 
 
The potential to raise Ab responses differed between the two analysed IL-2 peptides. IL-
26–20KK elicited a higher Ab seroreactivity accounting for 39% (n= 55) among RA patients 
and 7% (n= 10) in HCs (p< 0.0001, Fig. 6A), while Abs against IL-256–70 were detected in 
23% (n= 32) of RA subjects and 8% (n= 13) of HCs (p=0.0031, Fig. 6B).  
However, the highest levels of autoreactive Abs were directed against IRF5424–
434 observed in 56% (n= 79) of RA patients and only 9% (n= 13) of HCs (p<0.0001, 
Fig. 6C).  
Slightly lower prevalence was observed for anti-BOLF1305–320Abs found in 44% (n= 61) of 
RA subjects and 9% of HCs (p<0.0001, Fig. 6D).  
Responses against Herv-K-env19–37 and MAP_402718–32 were maintained at the same 
levels (9%) among HCs, while seroreactivity of RA patients equalled 24% 
(n= 34, p=0.0012, Fig. 6E) and 21% (n= 30, p=0.0076, Fig. 6F), respectively.  
Despite antigen-related differences in single-type Abs prevalence, all results attained 
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Fig. 6. ELISA-based analysis of Abs reactivity against human, viral and MAP-derived 
peptides in RA, NMOSD and HCs. The sera were tested against plate-coated IL-26–20KK (B), IL-
256–70 (A), IRF5424–434 (C), BOLF1305–320 (D), Herv-Kenv19–37 (E) and MAP_402718–32 (F) peptides. 
Bars represent the median ± interquartile range. Thresholds for Abs positivity are indicated by 
dashed lines. Percentages of Abs prevalence respective to each group, AUC and P-values are 
indicated above the distributions. 
 
Bo M et al. Scientific Reports, 2018 
The prevalence of Abs against both IL-2 epitopes was additionally assessed in 34 
samples of patients affected by neuromyelitis optica spectrum disorder (NMOSD). Only 
one patient displayed values above the established cut-off for IL-256–70 (2.9%, Fig. 6A) 
whereas lower means obtained for IL-26–20KK were mirrored by the absence of positive 
cases (Fig. 6B). Moreover, the responses of NMOSD patients were markedly lower 
compared not only to RA subjects, but also to HCs. 
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To test the specificity of humoral responses mounted against the selected peptides, 22 
HCs and 22 RA patients were randomly selected from the study population and tested for 
seroreactivity against J0I929_HELPX1–11 control peptide derived from Helicobacter pylori 
homologous to human ZnT8 (Masala S et al., 2015). In both groups, half number of 
samples tested positive to at least one (HCs) or all (RA) of the previously assessed 
peptides. The observed mean values were slightly higher for HCs and corresponded to 
the absence of positive subjects compared to 9% (n=2) among RA patients, however 
statistical significance was not attained (p=0.07). Interestingly, RA individuals with 
multiple Abs positivity presented lower mean values compared to HCs with single-peptide 
positivity (Fig. 7). 
Fig. 7. Abs reactivity against the antigenic peptide derived from H. pylori in RA patients 
and HCs. Bars represent mean value ± interquartile range, while dashed lines indicate the 
positivity threshold. Despite sequence homology to human ZnT8 protein fragment, no significant 
differences in Abs levels were detected. 
 
Bo M et al. Scientific Reports, 2018 
To define associations between the antigenicity of the assessed peptides, correlation 
analyses of Abs positivity values among RA patients was performed (Fig. 8). The highest 
coefficients were obtained for the homologous epitopes BOLF1305–320, MAP_402718–
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32 and IRF5424–434 in pairwise plots (Fig. 8A) pointing at cross-reactivity due to shared 
amino acid sequence. 
Correlation trends of both IL-2 peptides were similar with respect to the other antigens 
(Fig. 8B and Fig. 8C): Herv-Kenv19–37 and MAP_402718–32 correlated moderately with 
either IL-26–20KK or IL-256–70, however IL-256–70/Herv-Kenv19–37 distribution corresponded 
to a slightly higher R2 value (Fig. 8B). Unexpectedly, weak to modest correlations were 
found between IL-2, IRF5424–434 and BOLF1305–320 (Fig. 8C). 
Fig. 8. Scatter plots showing correlations between Abs titers in RA patients. Pairwise 
distributions are classified for homologous peptides (A), IL-26–20KK (B) and IL-256–70 (C). Each dot 
correspond to OD values obtained for a single patient. 
 
Bo M et al. Scientific Reports, 2018 
Dr. Bo Marco – “Immune response against Mycobacterium avium subsp. paratuberculosis, 
Epstein-Barr virus, HERV-K and IRF5 in rheumatoid arthritis” – PhD thesis in Life Sciences and 
Biotechnologies – University of Sassari, Italy 
54 
 
Further evaluation was performed to investigate multiple positivity against the assessed 
peptides in order to verify whether correlations between Ab titers find correspondence 
with the overlap in seroreactivity against IL-2 (Table 2). In contrast to mild correlations of 
both IL-2 epitopes plotted against IRF5424–434 or BOLF1305–320, double or triple humoral 
responses to these antigens were detected in a major number of subjects with distinctly 
higher percentages for IL-2/IRF5 reflecting single-peptide Abs prevalence. On the other 
hand, responsiveness to Herv-Kenv19–37 overlapped well with the presence of anti-IL-256–
70 Abs as expected from the correlation analysis and stood out also in triple positivity with 
positivity to IRF5424–434. Even though multiple responses among HCs are low in general, 
they visibly tend to diminish for Abs against at least three antigens. 
Table 2. Multiple Abs prevalence in RA patients and HCs. Seroreactivity against IL-2 
antigens was compared with humoral responses to MAP, EBV, HERV-K and human IRF5 
peptides. The numbers of subjects positive for anti-IL-26–20KK and/or anti-IL-256–70 Abs are 
reported with relative percentages in brackets. Horizontal bars indicate Abs against at least two 
antigens identified in the samples with IL-2 referred to as both IL-26–20KK and IL-256–70. p<0.0001 
for all values except aIL-256–70 (p<0.0002) and bIL-256–70 (p<0.0003). 
Bo M et al. Scientific Reports, 2018 
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Upon sex-related screening of RA samples, females showed higher mean Abs values and 
positivity prevalence for all peptides compared to males, however statistical significance 
was reached only for IRF5424–434 (p=0.034). After classification of RA patients and HCs in 
three age groups (≤49, 50–59 and ≥60), the highest responsiveness was observed for 
BOLF1, IRF5 and IL-26–20KK (Table 3). This trend was clearly visible in the youngest RA 
group regardless of sex, however females maintained it more stably until the age of 59. 
In contrast to men, humoral responses of RA and HCs women were not significant in the 
oldest group but this could be affected by a small number of elderly HCs in our study 
population. A general decrease in Ab positivity proportional to age was common to either 
male or female patients. Importantly, seroreactivity to IRF5 exceeded 93% in the youngest 
females and reached a 100% in ≤49 year-old males (one patient). 
Table 3. Age and sex related Abs prevalence in RA patients and HCs. The numbers of 
individuals responsive to single antigens are provided with relative percentages. Statistically 
significant values are highlighted in bold. 
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PCA analysis permitted to identify relationships between clinical variables and the 
selected epitopes with 79.17% of cumulative variation describing four principal 
components (Table 4). 
Table 4. Correlation coefficients between inflammation measures, demographic data and 
seroreactivity relative to the selected antigens. All correlations are expressed as squared 
cosines of the variables. 
 
Bo M et al. Scientific Reports, 2018 
Correlation between Ab values and two inflammatory parameters was low but attained a 
statistical significance that differed based on the analysed measure: ESR correlated to 
Ab values towards IL-2 and HERV-K, while CRP yielded higher coefficients in plots with 
the homologous MAP, EBV and IRF5 antigens. No correlation with other clinical data was 
found. 
Discussion 
Recent reports on the loss of self-tolerance to IL-2 in autoimmune diseases provided basis 
to evaluate the presence of anti-IL-2 Abs in Sardinian RA patients in association to 
antigens most frequently described as possible contributors to RA progression. The 
current results confirm the involvement of IL-2 in RA at higher rates compared to a French 
cohort (39% vs. 15%, respectively) (Pérol L et al., 2016) and is mirrored by a concomitant 
positivity to peptide antigens derived from EBV, HERV-K, MAP or human IRF5. The latter 
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has been linked to acute inflammation as a factor promoting polarization of macrophages 
towards an inflammatory phenotype in antigen-induced RA mouse models and driving 
Th1/Th17 responses (Krausgruber T et al., 2011), (Weiss M et al., 2015), (Weiss M et al., 
2013). 
In the present study, IRF5, together with the EBV surface tegument protein BOLF1 and 
IL-2, triggered the greatest response even though devoid of a good correlation with IL-2. 
This suggests that the association between the two human autoantigens may not be 
proportionally dependent on Ab titers but favour autoimmunity when a tolerance threshold 
is surmounted. In contrast, IRF5 correlated well with homologous BOLF1 and MAP 
epitopes pointing at molecular mimicry that leads to a probable cross-reactivity with the 
assessed environmental agents to which humans are constantly exposed. This was 
recently confirmed by the competitive inhibition assay in our previous study (Bo M et al., 
2018a). 
For IL-2, the best correlation was obtained in the plot with HERV-K. While reactivation of 
endogenous retroviral protein expression may elicit serological and cell-mediated 
responses, an uncontrolled expansion of Treg cells in subjects who lost self-tolerance to 
IL-2 or IRF5 may explain the development of autoimmunity. Interestingly, over 30% of the 
assessed RA cohort displayed anti-IL-2/IRF5 Abs in a highly significant double positivity 
(p<0.0001) and a more frequent multiple seroreactivity was observed in RA patients 
compared to HCs (Table 2). 
Major prevalence of Abs directed against all single peptides and higher mean Abs values 
obtained for RA females in a sex-related analysis point at a more grave disease course 
proper to women and highlight the involvement of IRF5.  
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This was mirrored by a strikingly high prevalence of Abs against IRF5 in the ≤49 year-old 
group independently of patients’ sex. An elevated general seroreactivity observed in the 
youngest group that decreases with age points at a strong immune responses 
accompanying early disease onset. 
A significant correlation between levels of anti-IL-2 Abs and measures of systemic 
inflammation (Table 4) is supportive of the hypothesis that anti-IL-2-driven impairment of 
Treg activity may alter autoimmune processes and inflammatory burden. Other than 
expected, no significant correlations have been found between disease severity, 
immunosuppressive treatment, RF and ACPA status with levels and positivity of anti-IL-2 
Abs. It should be acknowledged that all patients were under different immunosuppressive 
drugs at the moment of sample collection. The heterogeneity of treatment across subjects 
may have biased interpretation and significance of associations between humoral 
responses and inflammatory measures.  
Further analysis of IL-2 levels, quantification of INF-γ upon stimulation with the analysed 
peptides and Treg activity are needed to complete our observations. More numerous 
groups of the youngest patients at RA onset and elderly HCs would additionally permit to 
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PtpA and PknG proteins secreted by Mycobacterium avium subsp. paratuberculosis 
are recognized by sera from patients with rheumatoid arthritis: a case-control study 
The aim of this work was to evaluate the presence of Abs directed against two proteins of 
MAP in sera of RA subjects, which are crucial for the survival of the pathogen within 
macrophages. Moreover, we analyzed the correlation of immune response to both proteins 
with the following homologous peptides: BOLF1305-320, MAP_402718-32 and IRF5424-434 to 
understand how the synergic role of EBV and MAP infection in genetically predisposed 
subjects may lead to a possible deregulation of IRF5.  
Results 
84 RA patients (19 males, 65 females; median age 59.0 years) who met the 2010 
ACR/EULAR Classification Criteria for RA (criteria of the American College of 
Rheumatology) (Aletaha D et al., 2010) were enrolled at the Outpatient Clinic of the 
Rheumatology Unit, Department of Clinical and Experimental Medicine, University Hospital 
of Sassari, Italy. 
A total of seventy-nine HCs (25 males, 54 females; median age 46.7 years) were recruited 
at the Blood Transfusion Centre of Sassari, Italy. Demographic, clinical and laboratory 









Dr. Bo Marco – “Immune response against Mycobacterium avium subsp. paratuberculosis, 
Epstein-Barr virus, HERV-K and IRF5 in rheumatoid arthritis” – PhD thesis in Life Sciences and 
Biotechnologies – University of Sassari, Italy 
60 
 






Age, years 59.0 ± 9.9 46.7 ± 11.6  
Female sex, n (%) 65 (77.38) 54 (68.35)  
Disease duration, months 145 ± 134 -  
ACPA positivity, n (%) 68.6 -  
RF positivity, n (%) 74.5 -  
HAQ (0-3) 0.92 ± 0.73 -  
DAS-28 3.72 ± 1.38 -  
CRP, mg/dL 0.88 ± 0.96 -  
ESR, mm/h 30.7 ± 25.8 -  
Steroids use, n (%) 43.4 -  
DMARDs use, n (%) 66.3 -  
Anti-TNF use, n (%) 24.1 -  
Tocilizumab use, n (%) 12 -  
Abatacept use, n (%) 4.9 -  
 
Bo M et al. Journal of Inflammation Research, 2019 
Production of recombinant PtpA and PknG proteins is described in the materials and 
methods chapter. 
Abs against PtpA were found to be above positive level in 41 out of 84 (48.8%) RA patients, 
whereas 6 out of 79 (7.6%) HCs were positive in serum (AUC=0.7525, p=0.0001, Fig. 9A 
and Fig. 9C). Regarding PknG, 23 out of 84 (27.4%) RA patients, 8 out of 79 (10.12%) HCs 
were positive in serum (AUC=0.6554, p=0.0054, Fig. 9B and Fig. 9D). 
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Fig. 9. ELISA-based analysis of antibody reactivity against two proteins of MAP in RA subject and 
HCs. The sera were tested against plate-coated PtpA (A) and PknG (B) proteins. 
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A noteworthy correlation was found between PtpA and all homologous pairs (BOLF1, 
MAP_4027 and IRF5). The highest correlation was found between PtpA and MAP_402718-
32 (R2=0.4945; Fig. 10C) followed by BOLF1305-320 (R2=0.4876; Fig. 10A). IRF5424-434 results 
showed the lowest correlation with PtpA, compared to MAP_4027 and BOLF1305-320, but it is 
still well-founded to hypothesize a cross-reactivity between the two epitopes (R2=0.4293; 
Fig. 10E). On the other hand, lower correlations between PknG and all three homologous 
pairs was found compared to PtpA, i.e., (R2=0.2025; Fig. 10B) with BOLF1305-320, (R2=0.194; 
Fig. 10F) with IRF5424-434 and (R2=0.3259; Fig. 10D) with MAP_402718-32. The correlation 
analysis showed that EBV and MAP have a synergic effect in the pathogenesis of RA.  
Globally, RA subjects displayed a significantly increased positivity to PtpA protein compared 
to HCs with a high degree of statistical significance (Fig. 9A and Fig. 11A). However, a lower 
Dr. Bo Marco – “Immune response against Mycobacterium avium subsp. paratuberculosis, 
Epstein-Barr virus, HERV-K and IRF5 in rheumatoid arthritis” – PhD thesis in Life Sciences and 
Biotechnologies – University of Sassari, Italy 
62 
 
reactivity was found against PknG (Fig. 9B and Fig. 11A). Finally, a lower reactivity against 
MAP_402718-32 was observed when compared to that against PtpA and PknG, but with a 
statistical significance vs. HCs (22.6% vs. 3.8%, p=0.0004, Fig. 11B).  
No correlation was detected between anti-PtpA/PknG Abs, serological and clinical features 
of RA, including disease activity and the type of immunosuppressive treatment, with the 
exception of a marginal correlation between Abs against PtpA serum concentration and a 
number of tender and swollen joints (r=0.224, p=0.042 and r=0.279, p=0.010, respectively). 
In the linear regression analysis, performed adjusting for age and sex, a significant linear 
correlation between the number of swollen joints and the serum concentration of Abs against 
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Fig. 10. A-F) Scatter plot showing correlations between Abs titers recognizing (A) BOLF1305-
320 and PtpA, (C) MAP_402718-32 and PtpA, (E) IRF5424-434  and PtpA, (B) BOLF1305-320 and PknG, 
(D) MAP_402718-32 and PknG, (F) IRF5424-434  and PknG  in 84 RA patients and 79 HCs. Person’s 
correlation was calculated through Graphpad Prism 6.0 software.  
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Analyzing single, double, and triple positivity for PtpA, PknG and MAP_402718-32 peptide, 
we observed that 11 RA patients tested positive for all antigens, while no positivity was found 
in HCs (p=0.0007, Fig. 11A). These data showed that, in attempt to delete the pathogen, 
the immune system triggers an immune reaction against different portions of MAP but with 
a major reactivity against PtpA. 
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Fig. 11. A) Coincidence of seroreactivity to the PtpA, PknG proteins and MAP_402718-32 
peptide among Abs-positive RA and HCs subject. B) Prevalence of Abs directed against PtpA, 
PknG and MAP_402718-32 in RA patients and HCs. 
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The results showed that, generally, PtpA and PknG proteins are highly recognized in RA 
patients, which may be useful to analyze the molecular mechanisms in macrophages after 
MAP infection. It is thus helpful to understand how MAP grows inside the macrophage to 
understand its implication in RA pathogenesis. 
Discussion 
In this study, the link between MAP and macrophages in RA was further investigated, 
taking into consideration that different cell populations are involved in the autoimmune 
process. However, it became increasingly clear that macrophages are very important in 
the pathogenesis of RA, as they generate cytokines that enhance inflammation and 
contribute to destruction of bone and cartilage. Bacterial and viral infections and other 
environmental factors can modify the function of macrophages by modulating the 
expression of transcription factors. MAP is an intracellular bacterium that grows into the 
macrophages, and, for this reason, it may be suspected that this infection can lead to a 
dysregulation of these cells. 
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Analysing the immune response against PtpA and PknG, which are crucial proteins 
necessary for the survival of the pathogen within macrophages, in RA patients and HCs, it 
has been found that the Abs level against both MAP proteins is significantly higher in RA 
patient sera than HCs sera. Moreover, it may be supposed that these patients have been 
either exposed or infected with MAP, which supports the theory on the impact of MAP 
infection on the development of RA. In addition, the existence of a correlation among 
immune responses against MAP_4027, BOLF1, and IRF5 was evaluated. This is helpful for 
understanding how the synergic role of EBV and MAP infection in genetically predisposed 
subjects can lead to a possible deregulation of IRF5. 
The present results are in line with corresponding studies that showed that sera of sheep 
previously infected with MAP, as well as in Crohn’s disease and MS have a significantly 
higher levels of reactivity against PtpA (McNees AL et al., 2015), (Kuenstner JT et al., 2017), 
(Feller M et al., 2007), (Slavin YN et al., 2018). Similarly, a strong immune response found 
in RA patients compared to HCs points at PtpA as a candidate for the potential detection of 
humoral immune responses in human. Among different mechanism involved in RA 
pathogenesis, an interesting role is played by molecular mimicry and citrullination (Trouw 
LA et al., 2017). In fact, the presence of a statistically significant antibody response between 
RA and HCs against the citrullinated peptide of MAP_402718-32Cit must be highlighted. Using 
the Fisher's exact test, MAP_4027 peptide and citrullinated peptide in positive patients were 
compared. Results showed a statistical difference in RA patients (26% vs. 43%, p=0.0170) 
supporting the hypothesis of the involvement of MAP in RA. These two virulence factors 
interfering with signal transduction in the host and are secreted proteins necessary for the 
survival of the pathogen in the harsh environment presented by the macrophage (Bach H et 
al., 2006), (Bach E et al., 2018). 
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The noteworthy result towards MAP citrullinate peptide suggests that it is likely that MAP 
infection may trigger a citrullination process in the attempt to eliminate the pathogen by self-
feeding the autoimmune process. Significantly, by carrying out a bioinformatics analysis, 
PtpA and PknG proteins present in their primary sequence could be potentially citrullinated 
from the macrophage PAD after bacterial infection, triggering the inflammatory response 
(PtpA (Protein tyrosine phosphatase A; UniProtKB Accession number: A0A200GPK8) and 
PknG (Protein kinase G; UniProtKB Accession number: A0A202FS53)). It has now been 
established that citrullination, together with carbamylation, is a process that, although 
physiologically present in nature, is more exacerbated in autoimmune diseases. 
Furthermore, they are a predictive marker of the onset of the disease. This is significant 
because the silent stage of MAP when infecting cells in which the citrullination may occur, 
even the disease develops much later. Therefore, the next step in this research is to 
citrullinate these proteins and to evaluate the Ab response in subjects with active arthritis 
and those at onset in order to understand if citrullination is part of a process generated by 
the host to eliminate the pathogen. In future work, the reactivity towards PtpA and PknG in 
the different rheumatic diseases should be tested in order to analyse similarities and/or 
differences. 
Moreover, to understand the binding of MAP infection with RA in detail, it is planned to 
analyze the molecular pathways of macrophages in vitro and in mouse models of arthritis 
following MAP infection. This helps to understand what kind of molecules (cytokines and 
chemokines (McInnes IB 2007) are produced and how these can influence the activity of the 
other immune cells as the same macrophages and neutrophils (O'Neil LJ et al., 2019), 
(Weiss M et al., 2015), (Wright HL et al., 2014). Furthermore, the analysis of expression of 
some important transcription factors in the regulation of the immune response, such as IRF5 
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(Almuttaqi H et al., 2018), (Khoyratty TE et al., 2018), JUNB (Moon YM et al., 2017), with 
the RNA sequencing (RNA-seq) technique and qPCR will allow for a better understanding 
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Association between Lipoprotein Levels and Humoral Reactivity to Mycobacterium 
avium subsp. paratuberculosis in Multiple Sclerosis, Type 1 Diabetes Mellitus and 
Rheumatoid Arthritis 
A recent study in sheep and cattle showed that MAP uses cholesterol as a primary carbon-
based energy source during early stages of infection (Johansen MD et al., 2018). The uptake 
and trafficking of MAP in human cells seems to be favored in cholesterol-rich compartments 
which are slow to acidify (Keown DA et al., 2012). It has also been demonstrated that MAP, 
similar to other pathogenic mycobacteria (Mattos KA et al., 2014), (Brzostek A et al., 2009), 
(Pandey AK et al., 2008), (de Chastellier C et al., 2006), (Gatfield J et al., 2000), is able to 
manipulate host lipid metabolism and accumulate cholesterol within macrophages to 
establish infection (Johansen MD et al., 2019). 
In addition to that, as before mentioned, MAP has been associated with MS, T1DM, and RA 
through a molecular mimicry mechanism. 
Here, the correlation between humoral reactivity against MAP and serum lipoprotein levels 
has been investigated in subjects at T1DM risk (rT1DM) grouped by geographical 
background and in patients affected by MS and RA. 
Results 
In the present study, the following groups were formed based on the pathological condition: 
22 MS patients (1:1.4 male/female ratio; 40 years median age), 22 patients at T1DM risk 
(1:1.6 male/female ratio; 4 years median age), 22 RA subjects (1:2.7 male/female ratio; 49 
years median age) and 22 healthy controls (HCs; 2.7:1 male/female ratio; 37 years median 
age). 
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MS patients diagnosed according to the revised McDonald diagnostic criteria (Polman CH 
et al., 2011) were enrolled at the Neurological Clinic of the University Hospital of Cagliari, 
Italy. At the time of the study, 19 patients were diagnosed as relapsing remitting MS and 
3 as secondary progressive MS. The expanded disability status scale (EDSS) values 
ranged from 0 to 7.0 with the average of 1.93 average. Demographic, clinical and 
laboratory features of MS and HCs are summarized in Table 6. 
Table 6. Demographic and clinical characteristics of MS patients and HCs 
                                MS                                 HCs 
                                                             n=22                               n=22 
Age, years                               39.77 ± 12.53                  36.72±11.59 
Female, n(%)                          13(59.09)                        16(72.72) 
Cortisone                                  12 
No cortisone                                  10 
EDSS                                   2.53 ± 2 
Relapse, n(%)                                  13(59.09) 
RRMS, n(%) 
SPMS, n(%) 
                                 19(86.36) 
                                 3(13.63) 
_______________________________________________________________ 
MS, multiple sclerosis; HCs, healthy controls; EDSS, Expanded Disability Status Scale; RRMM, Relapsing-
Remitting MS; SPMS, Secondary progressive MS.  
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Subjects at T1DM risk were recruited in Sardinia at Diabetology ward, St. Michele Hospital 
of Cagliari and in mainland Italy at the Tor Vergata University Hospital of Rome. T1DM risk 
was intended as disease familiarity between first-degree relatives, detection of high-risk HLA 
alleles and/or presence of diagnostic autoantibodies (ZnT8, GADA, IA2A, IAA and/or ICA). 
All subjects were free from therapy. 
RA patients diagnosed according to the 2010 ACR/EULAR classification criteria were 
enrolled at the outpatient clinic of the Rheumatology Unit, Department of Clinical and 
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Experimental Medicine, University Hospital of Sassari, Italy. Collected data included: 
duration of RA, therapy (steroids, Tocilizumab, DMARDs and/or anti-TNF-α), levels of C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR) levels, positivity to rheumatoid 
factor and anti-cyclic citrullinated peptide (anti-CCP), Disease Activity Score-28 (DAS-28) 
and grade of disability defined through the health assessment questionnaire. Demographic, 
clinical and laboratory features of RA and HCs are summarized in Table 7. 
Table 7. Demographic and clinical characteristics of RA patients and HCs 
                                    RA                             HCs 
n=22 
Age, years                                        49.3 ± 8.5                   36.72±11.59 
Female, n(%)                                                 16(72.7)                      16(72.72) 
ESR, mm/h                                                 18.9 ± 15 
CRP, mg/dL 1.01 ± 0.9 
DAS28 score 3.15 ± 1.3 
HAQ score                                                 0.7 ± 0.6 
ACPA positivity, n(%)                                                 12(54.5) 
RF positivity, n(%)                                                 13(59) 
Steroid use, n(%)                                                 12(54.5) 
Steroid dose, mg/day                                                 1.58± 2.6 
DMARDs use, %                                                 14(63.6) 
TNFi use, % 
Tocilizumab use, %  
 
                                                4(3.3) 
                                                7(58.3) 
_________________________________________________________________ 
RA, rheumatoid arthritis; HCs, healthy controls; ESR, erythrocyte sedimentation rate; CRP,             
C-reactive protein; DAS-28, disease activity score-28 joints; HAQ, health assessment 
questionnaire; ACPA, anti-citrullinated peptide antibodies; RF, rheumatoid factor; DMARDs, 
disease-modifying anti-rheumatic drugs; TNFi, tumor necrosis factor-alpha inhibitors.  
Bo M et al. Microorganisms, 2019 
HCs were recruited at the Blood Transfusion Center of Sassari, Italy. 
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For each disease, 11 patients positive to MAP derived antigens (MAP+) and 11 MAP 
seronegative subjects (MAP-) were selected. The prevalence of MAP-specific Abs was 
assessed against MAP_402718-32 peptide highly recognized in MS and RA, and against at 
least one of the following MAP peptides homologous to zinc transporter 8 (ZnT8) or 
proinsulin fragments: MAP3865c133–141, MAP3865c125-133, MAP2404c70-85 and 
MAP1,4αgbp157-173. 
Indirect ELISA to detect Abs against MAP peptides was performed as described in material 
and methods. Quantification of lipoproteins (HDL, LDL/VLDL and TC) in serum samples has 
been analyzed in each disease as in material and methods discussed. 
Upon the analysis of differences in lipoproteins levels in each disease group, MS and RA 
patients showed significantly increased levels of high density lipoprotein (HDL), low density 
lipoprotein/very low density lipoprotein (LDL/VLDL) and total cholesterol (TC) in comparison 
with HCs (p<0.0001, Fig. 12A and Fig. 12C). These results are in line with studies in sheep 
challenged with MAP where total serum cholesterol levels were elevated at 9 weeks post-
inoculation (wpi) in comparison to uninfected animals (Johansen MD et al., 2018). In 
contrast, statistically significant difference between T1DM and HC subjects was found only 
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Fig. 12. Levels of serum lipoproteins determined through disease-specific analysis. Bars show 
values were determined in samples from patients A) with MS, B) at risk of T1DM (rT1DM) and C) 
affected by RA, each analyzed with reference to concentrations obtained for healthy controls (HCs). 
P-values are specified for each group when statistically significant. Standard deviation is shown for 
each bar. 
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Next, the concentrations of HDL, LDL/VLDL and TC were compared in the sera of MAP+ 
and MAP- subjects of each pathological condition. The following associations were searched 
to understand whether anti-MAP Abs indicative of a possible past exposure to the 
mycobacterium or ongoing silent infection associate with quantity variation of the host lipids: 
MS MAP+ vs. MS MAP-; MS MAP+ vs. HCs MAP+; MS MAP- vs. HCs MAP-. The same 
association analysis was done for T1DM and RA subjects. 
In MS, a significant difference in HDL levels was found between MAP+ and MAP- patients 
(p=0.0398, Fig. 12A). MS MAP+ showed high HDL concentrations when compared with HCs 
MAP+, (p=0.0001, Fig. 12A) and similar trends were observed between MS MAP- and HCs 
MAP- (p<0.0001, Fig. 12A). It is interesting to note the levels of HDL, LDL and TC were 
lower in HCs MAP+ than HCs MAP-, although statistical significance was not attained (Fig. 
12A-C). The respective analysis performed for LDL/VLDL provided significant results 
between all groups analyzed (Fig. 12B). Regarding TC concentrations, no difference was 
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found between MS MAP+ and MS MAP- but significantly higher levels were registered for 
MS MAP+ comparing to HCs MAP+ (p<0.0001, Fig. 12C) and for MS MAP- vs. HCs MAP- 
(p<0.0001, Fig. 12C). 
In summary, MS MAP+ subjects are characterized by a significant decrease in HDL levels, 
an increase in LDL/VLDL (Fig. 12A-B) and no difference in TC levels. It is to be highlighted 
that the concentrations of HDL, LDL/VLDL and TC in MS MAP+ were markedly elevated in 
comparison to MAP+ HCs. Following the comparison between MS MAP- and HCs MAP-, it 
emerged that the overall levels of lipoproteins are remarkably higher in MS MAP- subjects 
and exceed values registered for MS MAP+. This points at a possible implication of lipids in 
MAP infection. 
Several evidences showed that HDL, LDL and TC variations are associated with MS 
progression (Zhang Y et al., 2019), (Palavra F et al., 2013), (Tettey P et al., 2014). For this 
reason, association analysis of serum HDL, LDL and TC levels and disability status in MS 
MAP+ and MAP- patients were performed. Even though the general association analysis 
between EDSS and TC levels showed no correlation (R2 =0.06), it is noteworthy that after 
subdivision into MAP+ and MAP- groups a higher correlation coefficient between EDSS and 
TC levels were obtained in MS MAP+ than MS MAP- (R2 =0.14 vs. R2 =0.03). Overall, the 
highest correlation was observed between EDSS and LDL in MAP+ (R2 =0.55). EDSS 
correlated well with HDL in MS MAP+ (R2 =0.34), while low coefficient was obtained for the 
same variables in MS MAP- (R2 =0.05). In addition, the correlation analyses were performed 
between the Abs response to MAP_402718-32 peptide and TC, HDL and LDL levels, which 
resulted in higher coefficients for TC and HDL levels in MS MAP+ (R2 =0.358 and R2 =0.493, 
respectively). No correlation with TC, HDL and LDL levels was found in MS MAP- subjects. 
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Similarly, the assessment of possible lipoprotein variations in patients receiving cortisone 
therapy revealed no difference. 
In subjects at T1DM risk, no difference in HDL levels was observed between the analyzed 
groups (Fig. 12D). In contrast, significantly lower LDL/VLDL concentrations were found 
among T1DM MAP- compared with T1DM MAP+ subjects (p=0.0080, Fig. 12E). Statistically 
significant reduction of TC levels among MAP- subjects were obtained in all association 
groups: T1DM MAP+ vs. T1DM MAP-, T1DM MAP+ vs. HCs MAP-, T1DM MAP- vs. HCs 
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Fig. 12. Disease-related concentrations of HDL, LDL and TC assessed based on positivity to 
MAP antigens. The analysis was performed by comparing MAP+ vs. MAP- subjects among patients 
affected by MS (A-C), at risk of T1DM (rT1DM) (D-F) and RA subjects (G-I). Additionally, comparison 
of between patients and healthy controls (HCs) was carried out for the same MAP-related serological 
status. Statistical significance is reported above relative bars when attained. For each group, 
standard deviation is indicated. 
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After classifying patients based on their geographic provenience, significantly higher levels 
of HDL (p<0.0001) and lower LDL (p<0.0001) and TC (p=0.0044) concentrations were 
observed in the group from mainland Italy compared to samples collected in Sardinia (Fig. 
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13A), which were mirrored by trends in MAP+ and MAP- subjects considering location of 
enrollment (Fig. 13B). 
Fig. 13. Concentrations of lipoproteins in subjects at risk of T1DM (rT1DM) grouped according 
to their geographic provenience. A) Comparison between patients enrolled in mainland Italy (IT; 
n=10) and Sardinia (SA; n=12). B) Differences in lipoprotein levels between IT and SA participants 
grouped according to their serological response to MAP antigens. Mean and standard deviation are 
indicated for each bar. 
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Upon the analysis of lipoprotein levels in RA, results showed a statistical difference in HDL 
concentrations between RA MAP+ and RA MAP- and when comparing RA MAP- with HCs 
MAP- (p<0.0001, Fig. 12G). Insignificantly lower HDL concentrations were found among RA 
MAP+ respect to RA MAP- (Fig. 12G). Increased levels of LDL/VLDL were observed in RA 
MAP+ vs. HCs MAP+ (p=0.0024, Fig. 12H) and in RA MAP- vs. HCs MAP- (p=0.0052, Fig. 
12G), however comparison between RA MAP+ and RA MAP- showed no difference. Similar 
results were obtained for TC (Fig. 12I) with strikingly lower levels among HCs regardless of 
anti-MAP Abs status (p<0.0001, Fig. 12I). 
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The outcomes of this study have shown variations in serum cholesterol levels associated 
with the presence of anti-MAP Abs. 
Genome-wide association study (GWAS) identified over 100 distinct genetic variants 
associated with MS predisposition (Dendrou CA et al., 2015) which genetic modulation of 
lipid profiles in disability progression. Less is known about environmental MS contributors 
and their link with genetically conferred susceptibility to infections. Recent evidences 
associate serum lipid levels and lipid-related polymorphisms with disability progression in 
MS patients (Polman CH et al., 2011). Cholesterol synthesis appears crucial during 
remyelination of neuroglia (Voskuhl RR et al., 2019) while its excess in plasma may 
aggravate neuronal cell damage (Zhornitsky S et al., 2016), thus conflicting results have 
been obtained for lipoprotein concentrations and degree of disability in this disease 
(Tettey P et al., 2014), (Zhang Y et al., 2019), (Voskuhl RR et al., 2019). The present 
results indicated higher levels of serum lipoprotein levels in MS patients, showing lower 
HDL concentrations among MAP+ subjects which correlated with higher EDSS. It is 
possible that lipid-related SNPs inducing imbalance of cholesterol favoring thereby 
mycobacterial survival in macrophages. This hypothesis would need a further screening 
for relevant gene polymorphisms and assessment to which extent MAP may alter 
lipoprotein homeostasis. A study in C57BL/6J mice highlights the ability of myelin 
oligodendrocyte glycoprotein MOG35–55 peptide from heat-killed MAP to induce 
experimental autoimmune encephalomyelitis (EAE) considered a model condition for MS 
studies (Cossu D et al., 2019). In addition, EAE was more severe in MAP-immunized mice 
than in animals treated with Freud's Complete Adjuvant (CFA) - a nonspecific stimulator 
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of the immune response. Still, MAP components were able to activate a strong 
proliferative T cell response. 
Differences in lipoprotein levels between patients at T1DM risk with distinct 
biogeographical background indicating possible genetic and environmental determinants 
are noteworthy. Low HDL and raised LDL levels are a typical feature of young T1DM 
patients at high cardiovascular disease (CVD) risk and were detected among Sardinian 
participants, while opposite trends were displayed by subjects from mainland Italy. The 
island of Sardinia is characterized by the second highest prevalence of T1DM worldwide 
(Group. 2006) and the by peculiar genetic heritage of local populations due to long lasting 
genetic isolation (Lampis R et al., 2000). Over 60% of Sardinian livestock herds seem to 
be infected with MAP (Masala S et al., 2011), however these estimates may reach more 
elevated numbers given the lack of official registers and monitoring strategies. Markedly 
high concentrations of LDL in Sardinian patients compared to the study group enrolled in 
Rome reflect observations in MAP-infected animals and may be indicative of past 
exposure to MAP in combination with gene variants facilitating or enhancing the effects 
of infection. On the other hand, slightly differing concentrations of serum lipoproteins 
between MAP+ and MAP- subjects within the same geographically-related group may 
present a temporary picture of a latent infection when MAP is not actively modulating 
lipoprotein profiles and should be further investigated in larger cohorts. 
Genetic regulation of lipid metabolism, particularly in the context of gene–environment 
interaction, has not been examined in the RA population. This may be particularly important, 
since lipid alterations appear to predate the diagnosis of RA (Kitas GD et al., 2010) and may 
be exacerbated during initial phases of MAP infection. Results obtained for RA cohort in this 
study are discordant compared to literature, although similar differences in lipoprotein levels 
Dr. Bo Marco – “Immune response against Mycobacterium avium subsp. paratuberculosis, 
Epstein-Barr virus, HERV-K and IRF5 in rheumatoid arthritis” – PhD thesis in Life Sciences and 
Biotechnologies – University of Sassari, Italy 
79 
 
have been described for distinct animal species. Upon exposure to different MAP strains, a 
significant increase in total serum cholesterol has been observed after 9 weeks post 
infection (wpi) in sheep, while cattle showed an opposite trend at 13 wpi (Johansen MD et 
al., 2018). The way in which cholesterol is exploited by MAP in varying time laps depends 
therefore on the host and host-specific mycobacterial strains. Lower but not significant 
lipoprotein levels detected among RA MAP+ patients compared to RA MAP- in our study 
may reflect MAP infection phase which at the initial stage is silent and difficult to diagnose 
(Whittington RJ et al., 2012). High HDL, LDL and TC levels in RA subject respect to 
healthy population and elevated values for the latter two in RA MAP+ versus HCs MAP+ 
can be due to different genetic determinants facilitating MAP infection and lipid content in 
this disease. The evaluation of such interplay may be complex as lifelong therapy 
administered to RA patients targets elements of the immune system resulting in 
suppressed responses to antigens in general and may affect cholesterol metabolism 
(Santosa S et al., 2007). 
Considering the complicated relationship between MAP and other factors involved in 
autoimmune processes that lead to an imbalance in lipoprotein levels, follow-up studies 
and employment of murine models representing the corresponding diseases (MS, T1DM 
and RA) will allow to monitor the relationship between anti-MAP immune responses and 
cholesterol levels and to explore mechanisms through which the mycobacterium may 
favor pathological phenotypes. Supposedly, dependence of MAP survival on cholesterol 
is not only confined to the first stage of infection but continues later during possibly 
prolonged silent state which may be dominant in not primary hosts such as humans. A 
slow release of cholesterol previously accumulated by MAP inside macrophage may be 
released during gradual killing of the pathogen, thus leading to a variation in lipoprotein 
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levels. A successful isolation of MAP along with strain characterization would shed light 
on strain-specific functional differences in lipid regulation and immune responses. This 
would help to position MAP in complex molecular pathways underlying described 
autoimmune conditions. For the time being, preliminary results presented here need to 
be confirmed in a larger cohort and an accurate evaluation of confounding factors such 
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Antibody response to epitopes of Epstein-Barr virus, Mycobacterium avium subsp. 
paratuberculosis and IRF5 in connective tissue diseases 
Results 
Improve knowledge to different biomarkers is useful for diagnosticate rheumatic diseases 
early and provide important insights for clinical management. This study evaluates the 
frequency of reactivity of sera of patients with different connective tissue diseases (CTDs) 
(RA, SLE, SSc and SSj) to IRF5 and homologous peptides from EBV and MAP. Experiments 
in mouse models of arthritis, as discussed below, have been performed at the Kennedy 
Institute of Rheumatology (University of Oxford) for reinforce the idea that Abs against three 
homologous peptides that we used are cross-reactive. Reactivity against wild-type (wt) and 
citrullinated (cit) IRF5 (IRF5424-434), MAP (MAP_4027
18-32
) and EBV (BOLF1305-320) peptides 
was tested by indirect ELISA in sera from 100 RA patients, 54 patients with other CTDs (14 
SLE, 28 SSc and 12 SSj) and 100 HCs. Sera to mouse models of arthritis have been tested 
to analyze the antibody response to wt peptides. Demographic and clinical features of all 
subjects involved in this study are summarized in the Table 8 and Table 9. 
Table 8. Demographic and clinical characteristics of groups 
        RA 
     n=100 
      SLE 
      n=14 
     SSc 
     n=28 
     SSj 
    n=12 
     HCs 
    n=100 
Age, years 57.6 ± 10.3 36.5 ± 11.2 58.9 ± 13.2 59.5 ± 15.4 45.1 ± 11.7 
Female, n(%) 80(80) 14(100) 23(82) 12(100) 74(74) 
DAS28 3.45 ± 1.7 / / / / 
SLEDAI / 3.42 ± 4.7 / / / 
ESCsG-AI / / 2.23 ± 2.1 / / 
ESSDAI / / / 2.83 ± 2.16 / 
RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; HCs, healthy 
controls. DAS-28, disease activity score-28 joints; SLEDAI, systemic lupus erythematosus disease 
index 2000; ESCsG-AI, European Scleroderma Research Group Activity Index; ESSDAI, EULAR 
Sjogren's syndrome disease activity index. 
 
Bo M et al. Unpublished data, 2019 
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Age, years 57.6 ± 10.3 45.1 ± 11.7 
Female, n(%) 80(80) 74(74) 
ESR, mm/h 19.5 ± 25 / 
CRP, mg/dL 1.34 ± 4.8 / 
DAS28 score 3.45 ± 1.7 / 
HAQ score 1.04 ± 0.9 / 
ACPA positivity, % 65(65) / 
RF positivity, % 73(73) / 
Steroid use, % 64 / 
Steroid dose, mg/day 1.5 ± 2.3 / 
DMARDs use, % 86 / 
TNFi use, % 27 / 
Tocilizumab use, % 13 / 
Abatacept use, % 4 / 
Rituximab use, % 2 / 
 
RA, rheumatoid arthritis; HCs, healthy controls. ESR, erythrocyte sedimentation rate; CRP, C-
reactive protein; DAS-28, disease activity score-28 joints; HAQ, health assessment questionnaire; 
ACPA, anti-citrullinated peptide antibodies; RF, rheumatoid factor; DMARDs, disease-modifying 
anti-rheumatic drugs; TNFi, tumor necrosis factor-alpha inhibitors.  
 
Bo M et al. Unpublished data, 2019 
Wt-BOLF1305-320 elicited the highest seroreactivity accounting for 53% (n=53) among RA 
patients,  7.14% (n=1) in SLE, 32.1% (n=9) in SSc, 7.69% (n=1) in SSJ and 5% (n=5) in 
HCs (p=0.0001; Fig. 14A), while Abs against cit-BOLF1305-320 were detected in 21% (n=21) 
of RA subjects, 21.4% (n=3) in SLE, 7.14% (n=2) in SSc and 7.69% (n=1) in SSj and 5% 
(n=5) of HCs, (Fig. 14D). Also, a statistically significant difference was found between SSc 
and HCs (32.1% vs. 5%, respectively, p=000.3; Fig. 14A) for BOLF1 that highlights the role 
of EBV in SSc.  
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In RA and SSc, the wt-BOLF1305-320 elicited a greater reactivity than its citrullinated 
counterpart (p=0.0001 and p=0.0403 respectively), while no statistically significant 
difference was attained in SLE and SSj groups (Fig. 14G).  
 
Regarding MAP peptides, wt-MAP_402718-32 elicited the highest seroreactivity among RA 
patients accounting for 26% (n=26), 14.29% (n=2) in SLE, 28.57% (n=8) in SSc, 15.38% 
(n=2) in SSj and 8% (n=8) in HCs, (p=0.0001; Fig. 14B), while Abs against cit-MAP_402718-
32 were detected in 43% (n=43) of RA subjects, 28.57% (n=4) in SLE, 10.71% (n=3) in SSc, 
0% in SSj and 6% (n=6) of HCs (p=0.0001; Fig. 14E). SSc and HCs significantly differed 
when considering values obtained for MAP_402718-32 (p=0.0076; Fig. 14B). Of note, a 
statistical difference was registered in RA patients between the proportion of anti-wt-
MAP_402718-32 and anti-cit-MAP_402718-32 (26 vs. 43%, p=0.0170; Fig. 14H). 
IRF5 peptide elicited a higher seroreactivity reaching 73% (n=73) among RA patients, 7.14% 
(n=1) in SLE, 32.1% (n=9) in SSc, 23.1% (n=3) in SSJ and 9% (n=9) in HCs (p=0.0001, Fig. 
14C), while Abs against cit-IRF5 peptide were detected in 14% (n=14) of RA subjects, 14.3% 
(n=2) in SLE, 10.7% (n=3) in SSc, 7.69% (n=1) in SSj and 10% (n=10) of HCs (Fig. 14F). A 
significant difference was observed for IRF5424-434 between SSc and HCs (p=0.0042; Fig. 
14C). We then compared the antibody response against wt-IRF5 peptide versus its 
citrullinated variant in all disease-specific groups. The proportion of anti-wt-IRF5 vs. anti-cit-
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Fig. 14. A-F) ELISA-based analysis of Abs reactivity against human, viral and MAP-derived 
peptides in RA patients, SLE, SSc, SSj and HCs. The sera were tested against plate-coated 
BOLF1305-320 (A), MAP_402718-32 (B) and IRF5424-434 (C) peptides. Also, the sera were tested 
against plate-coated BOLF1305-320 Citrullinated (D), MAP_402718-32 Citrullinated (E) and IRF5424-
434 Citrullinated (F) peptides. Bars represent the median ± interquartile range. Thresholds for 
Abs positivity are indicated by dashed lines. P-values are indicated above the distributions. 
(G-I) Mean distribution of OD values and Fisher's exact test. *P<0.05; **P=0.001; ***P=0.0001; 
****P<0.0001. 
  
Bo M et al. Unpublished data, 2019 
Although there was no statistical significance for the assessed peptides in SLE, SSc and 
SSJ compared to RA, we performed correlation analyses of Abs positivity values among 
SLE, SSc and SSJ patients (Fig. 15 and Fig. 16). The highest coefficients were obtained for 
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the homologous epitopes BOLF1305-320, MAP_402718-32 and IRF5424-434 in pairwise plots 
pointing at cross-reactivity due to shared amino acid sequence (Fig. 15).  
Fig. 15. A-I) Scatter plot showing correlations between Abs titers recognizing BOLF1305-320 and 
MAP_402718-32, MAP_402718-32 and IRF5424-434, BOLF1305-320 and IRF5424-434 in SLE (A, B, C), SSc 
(D, E, F) and SSJ (G, H, I) patients. Person’s correlation was calculated through Graphpad Prism 
8.0 software. 
 
Bo M et al. Unpublished data, 2019 
The lack of correlation was found for all homologous pairs of citrullinated peptides, with the 
exception observed between cit-BOLF1305-320 and cit-MAP_402718-32 in SLE (R2=0.8439; 
Fig. 16A). Similarly, cit-BOLF1305-320 and cit-IRF5424-434 highly correlated in SSJ (R2 =0.906; 
Fig. 16I). 
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Fig. 16. A-I) Scatter plot showing correlations between Abs titers recognizing BOLF1305-320Cit and 
MAP_402718-32Cit, MAP_402718-32Cit and IRF5424-434Cit, BOLF1305-320Cit and IRF5424-434Cit in SLE (A, 
B, C), SSc (D, E, F) and SSJ (G, H, I) patients. Person’s correlation was calculated through 
Graphpad Prism 8.0 software. 
 
Bo M et al. Unpublished data, 2019 
Discussion 
The present study demonstrated that the Abs response to IRF5, EBV and MAP homologous 
peptides is different across CTDs, with RA sera showing the most significant reactivity 
against either wild-type or citrullinated peptides. These results confirmed the previous data 
on RA (Bo M et al., 2018a) (Bo M et al., 2018c). AIA model has been useful for reinforce the 
results obtained in humans as discussed below. The antibodies formed after CFA 
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inoculation could lead to cross-reactions towards MAP antigens triggering a persistent 
inflammation towards IRF5 and EBV, typical condition of autoimmune diseases. To validate 
this hypothesis, it is planned to analyze the immune responses in irf5 -/- mice in order to 
understand if the Abs are able to cross-react at the same way. This could be helpful to 
broaden the knowledge on IRF5 role and on the base of results understand how is possible 
intervene for blocking autoantibodies production able to trigger chronic inflammation. In 
addition, it would be interesting to test the reactivity against the homologues citrullinated 
peptides in order to compare the results. Citrullination, a fundamental and ubiquitous post-
translational modification with potentially relevant effect on the induction of secondary 
autoimmune responses, may be triggered by various infective agents, mainly at the level of 
mucosal surface. Therefore, it is plausible that also EBV and MAP may induce citrullination 
of protein fragments, hence antigenicity of citrullinated homologous peptides derived from 
IRF5, EBV and MAP was tested. Intriguingly, the response against cit-MAP_402718-32 was 
significantly higher than that against its wild-type variant, suggesting the role of MAP 
citrullinated antigens as possible triggers of autoimmunity in RA supported by the production 
of specific ACPA. However, with the exception of anti-cit-IRF5, in RA and other CTDs, 
seroreactivity to the other two citrullinated peptides was similar and in some instances even 
significantly lower than responsiveness against their wild-types counterparts.  
For the first time in this study, a significant Abs response to homologous peptides of IRF5, 
MAP and EBV was also shown in SSc patients. It has been demonstrated that exposure to 
EBV is able to infect human dermal fibroblasts in vitro, inducing pro-fibrotic phenotypic 
switching, a relevant pathogenetic pathway underlying skin fibrosis in SSc (Farina A et al., 
2014). Moreover, EBV viral transcripts and proteins were demonstrated in fibroblasts and 
endothelial cells in the skin of SSc patients (Farina A et al., 2014). EBV chronic replication 
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in SSc primary monocytes has been proven to activate TLR8 molecular pathway sustaining 
monocyte-derived inflammation in SSc (Farina A et al., 2017). In addition, higher frequency 
of Abs against EBV has been recently demonstrated in SSc compared to healthy controls. 
Collectively taken, these data suggest that EBV-specific response may be an initiating 
trigger of SSc, with persistent viral infection-related tissue injury underlying chronic 
inflammation and fibrosis. It is probable that a defective type I IFN-mediated signaling may 
blunt anti-viral responses and EBV infection control in patients with SSc, as recently 
demonstrated in MS (Severa M et al., 2019). Interestingly, the number of minor rs4728142 
alleles of IRF5 has been described as a predictive factor of a longer survival in SSc patients 
(Roozbeh Sharif et al., 2012). Therefore, it is conceivable that Abs-mediated modulation of 
IRF expression/function in SSc may have an impact on the pathogenesis and severity of the 
disease. 
The significant reactivity of SSc sera against MAP peptides demonstrated in the present 
study is intriguing and worth of further investigation. Although preliminary, the obtained data 
suggest that SSc and RA patients actuate a similar autoimmune response to MAP-derived 
antigens pointing at MAP infection as a common pathogenetic contributor to various CTDs. 
Weak or insignificant immune response to the assessed epitopes among patients with SLE 
and SSj further supports the concept that (auto)immune responses to environmental 
pathogens are variable across CTDs. 
This study has limitation that all patients were subjected to different immunosuppressive 
therapies at the moment of sample collection, a fact that may have biased the interpretation 
and significance of humoral responses.  
Further analysis of pro-inflammatory cytokine levels and quantification of INF-γ upon 
stimulation with the analyzed peptides could have strengthen the present observations. In 
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addition, a study of diagnostic performance of Abs against the selected peptides, has not 
been performed due to limited sample sizes of non-RA CTDs sera. 
Also, analysis of immune response against the above peptides in irf5-/- mice will be useful 
in order to understand the cross-reactivity among peptides. 
The diagnostic performance of antibodies to BOLF1, MAP and IRF5 homologous peptides 
in differentiating between healthy controls and CTDs and between different CTDs, needs to 
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Investigating the immune response against the homologous peptides (BOLF1305-320, 
MAP_402718-32, IRF5434-424) in AIA, CIA and CAIA sera of mice 
Results 
In order to better understand the etiopathogenesis of RA involving largely unknown genetic 
and environmental factors, animal models have been extensively employed for studies 
focused on molecular mechanisms underlying human diseases with the objective to develop 
new therapeutic strategies (Bevaart L et al., 2010), (McNamee K et al., 2015), (Kollias G et 
al., 2011). A number of rodent models of arthritis have been generated over decades of 
research in the field and among them mouse models of RA share many features with the 
relative disease in humans. 
To validate the hypothesis of cross-reactivity, AIA mouse model was employed in this study 
for the assessment of immune responses against peptides derived from EBV and MAP 
sharing sequence homology with IRF5. Mice were grouped in the following treatment 
conditions: n=6 naïve mice not subjected to immunization, n=5 immunized mice and n=55 
AIA mice. Arthritis was induced at ∼12 wk of age as described elsewhere (Egan PJ et al., 
2008), (Parsey MV et al., 1998). Briefly, after sedation with inhaled isoflurane at day zero 
(D0), mice were immunized with mBSA (Sigma, 100 µg) emulsified in complete Freud’s 
adjuvant (Difco, 100 µg) and subsequently administered subcutaneously at the base of the 
tail. Seven days later (D7), arthritis was induced in sedated mice by intraarticular injection 
of mBSA using a sterile 33-gauge microcannula. Treatment with PBS alone was used as a 
control condition. Spleen, knee joints and blood were harvested on days 9-14 from sacrificed 
mice (Fig. 17B). Blood was centrifuged at 2000 rpm for 20 minutes to separate serum for 
serological analysis. 
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The reactivity to three homologous peptides IRF5, BOLF1 and MAP was tested in serum of 
three arthritis models (AIA, CIA and CAIA) and revealed a different response. 
The results obtained highlight a statistical difference between D1 and D7 and D2 and D7 for 
BOLF1, between D2 and D7 for MAP_4027 and between D1 and D7 for IRF5 in the AIA 
model (Fig.17: A, B, C, D, E, F). No statistical difference for the same peptides was found in 
the CIA and CAIA models (data not shown). 
Fig. 17. A) Schematic diagram showing treatment and harvest time points in the antigen-induced 
arthritis model. B) Sequence alignment between human and mouse IRF5 protein. The red circle 
shows the homologue sequence between IRF5, MAP and EBV antigen. C) Antigen- Induced arthritis 
(AIA) knee swelling time course. Comparison of knee swelling between inflamed knees of the AIA 
and WT animals, expressed as a percentage of swelling of the mBSA-challenged knee compared 
with the PBS knee. D-F) ELISA-based analysis of Abs reactivity against EBV, MAP and IRF5 
peptides AIA (Antigen-Induced arthritis) mouse model.  
 
Bo M et al. Unpublished data, 2019 
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AIA model has been useful for reinforce the results obtained in humans. The Abs formed 
after CFA inoculation could lead to cross-reactions towards MAP antigens triggering a 
persistent inflammation towards IRF5 and EBV, typical condition of autoimmune diseases. 
To validate this hypothesis, we plan to analyze the immune responses in irf5 -/- mice in order 
to understand if the Abs are able to cross-react at the same way. This could be help for 
broaden the knowledge on IRF5 role and on the base of results understand how is possible 
intervene for blocking autoantibodies production able to trigger chronic inflammation. In 
addition, will be interesting test the reactivity against the homologues citrullinated peptides 
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CHAPTER 5: Conclusions 
RA is a complex chronic inflammatory disease which could be triggered as a 
consequence of an environmental pressure in genetically susceptible subjects. RA 
causative agents remain to be determined, despite the fact that a number of studies have 
been set up in order to discover a putative etiological agent.  
For the first time, has been searched a humoral response in patients with RA and controls 
against four surface epitopes of HERV-K env-su (HERV-K env-su19–37, HERV-K env-
su109–126 and HERV-K env-su209–226). Among them, the most interesting peptide was 
HERV-K env-su19–37, which was recognized in the sera of 19% of RA patients and in 
only 3% of controls. 
Data from this study demonstrated a remarkable reactivity of RA sera against IRF5 
supporting the potential role of IRF5 as an important target in RA specific autoimmunity. 
Moreover, it has been also demonstrated a high grade of cross-reactivity between IRF5, 
EBV and MAP epitopes. A possible explanation for these results could be that in RA 
patients past EBV and/or MAP infection may induce specific humoral immunity reacting 
against IRF5 host protein. This secondary response may contribute, through the epitope-
spreading phenomenon, to synovial tissue destruction with the production of Abs against 
previously “sequestered” antigens and amplification of autoimmune cascade. 
In addition, recent reports on the loss of self-tolerance to IL-2 in autoimmune diseases 
encouraged my studies to evaluate the presence of anti-IL-2 Abs in Sardinian RA patients 
in association to antigens most frequently described as possible contributors to RA 
progression. The results confirm the involvement of IL-2 in RA at higher rates compared 
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to a French cohort (39% vs.15%, respectively) and is mirrored by a concomitant positivity 
to peptide antigens derived from EBV, HERV-K, MAP or human IRF5. 
In addition, research performed on RA Sardinian patients, showed MAP is another one 
of the candidates that could have a role of the environmental trigger. However, in this 
scenario, it is still too early to say whether cross-recognition between MAP and EBV 
antigens and homolog human protein as IRF5 involves an epitopes mimicry phenomenon 
starting or precipitating RA. For these reasons, to prove that MAP and EBV infection plays 
a causal role in RA, animal model studies should be performed in order to have a global 
vision of the situation. 
To date, the evidences is not enough in order to prove a causal relationship between 
MAP, HERV-K, EBV and RA. What we can say is that we showed an evident association 
of EBV, HERV-K and MAP with RA in Sardinia. It's not unlikely that MAP is one of the 
environmental factors that trigger the autoimmune process in genetically predisposed 
people after infection through water or milk ingestion in early life, but other roles are 
possible.  
It will be necessary to perform other studies about the link between HLA genes and 
infections in order to better understand the progression of infected patients with a chronic 
autoimmune stage and the containment of the process in HCs. This discover could help 
the clinicians in order to improve the therapeutic approach to the disease, so will be 
important to improve diagnostic biomolecular tests for detecting the MAP presence in the 
early stage of infection and not too late. 
Future research will help to discover in which molecular pathways EBV, HERV-K and 
MAP are involved in RA pathogenesis helping in turn to discover the specific regions 
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targeted by the immune system. At the same way, it will be important to develop new 
vaccines based on these regions in order to protect individuals with HLA predisposition 
to develop RA. Considering the particular background of Sardinian subjects and the 
complexity of RA disease, the development of  alternative approaches, could be useful in 
order to better take into account the specific need of each patient. The contribute of other 
researchers around the world will be important to get other steady and consolidate results 
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CHAPTER 6: Materials and Methods 
Patients and controls 
RA, SLE, SSc and SS patients were enrolled at the outpatient clinic of the Rheumatology 
Unit, Department of Clinical and Experimental Medicine, University Hospital of Sassari, 
Italy. 
Collected data about RA patients included: duration of RA; steroid treatment; DMARDs 
and/or anti-tumour necrosis factor-alpha therapy, Tocilizumab, Rituximab and Abatacept; 
levels of C-reactive protein (CRP), mg/dL; erythrocyte sedimentation rate (ESR) levels, 
mm/h; rheumatoid factor positivity; anti-cyclic citrullinated peptide positivity (anti-CCP); 
Disease Activity Score-28 (DAS-28) and Health Assessment Questionnaire (HAQ). RA 
patients met the criteria of the American College of Rheumatology (Arnett FC et al., 1988) 
(Aletaha D et al., 2010). 
The following disease-specific activity scores were also registered: SLEDAI (Systemic 
lupus erythematosus disease index 2000, for SLE; (Gladman DD et al., 2002), ESCsG-AI 
(European Scleroderma Research Group Activity Index, for SSc; (Valentini G et al., 2001)) 
and ESSDAI (EULAR Sjogren's syndrome disease activity index, for SSj; (Seror R et al., 
2010)). 
MS patients diagnosed according to the revised McDonald diagnostic criteria (Polman CH 
et al., 2011) were enrolled at the Neurological Clinic of the University Hospital of Cagliari, 
Italy. At the time of the study, 19 patients were diagnosed as relapsing remitting MS and 
3 as secondary progressive MS. The expanded disability status scale (EDSS) values 
ranged from 0 to 7.0 with the average of 1.93 average. Demographic, clinical and 
laboratory features of MS are summarized in Table 6. 
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NMOSD patients (5 males, 29 females; median age 51.32) were enrolled at the Neurology 
Clinic of the University Hospital of Sassari and at the Department of Neurosciences, 
Biomedicine and Motion, University of Verona, Italy.  All patients were onset free from 
immunomodulatory/immunosuppressive therapy over the last 12 months. The diagnosis of 
NMOSD was based on established criteria  (Uzawa A et al., 2012); all sera were tested for 
Abs to AQP4 through the commercially available Anti-Aquaporin-4 IIFT screening test 
(Euroimmun, Germany) (Uzawa A et al., 2014) and to myelin oligodendrocyte glycoprotein 
(MOG) using recombinant live cell-based immunofluorescence assay with HEK293A cells 
transfected with full-length MOG, as described elsewhere (Di Pauli F et al., 2011). 
Subjects at T1D risk were recruited in Sardinia at the Department of Diabetes, St. Michele 
Hospital of Cagliari and in mainland Italy at the Tor Vergata University Hospital of Rome. 
T1D risk was intended as disease familiarity between first-degree relatives, detection of 
high-risk HLA alleles and/or presence of diagnostic autoantibodies (ZnT8, GADA, IA2A, IAA 
and/or ICA). All subjects were free from therapy. 
HCs patients were recruited at the Blood Transfusion Centre of Sassari, Italy. 
Mice 
Antigen-Induced Arthritis (AIA) 
Antigen-Induced Arthritis (AIA) mouse model has been induced by a certified competent 
person at the Kennedy Institute of Rheumatology, University of Oxford with mBSA + 
Complete Freund’s Adjuvant following the instruction in literature (Asquith DL et al., 2009) 
(Egan PJ et al., 2008). More precisely, at day 0, mice were sedated using inhaled isofluorane 
anesthesia and then immunized with 100 µg of mBSA (Sigma) emulsified in 100 µl of 
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complete Freud’s adjuvant (BD Difco), administered subcutaneous at the base of the tail 






Fig. 18. Immunise of mouse 
At day 2, 3 and 7, we induced arthritis by means of an intraarticular injection of BSA in 
sedated animal. Then the mice were killed, the knee joints were excised for the study of cell 
populations in this site of inflammation through FACS analysis, blood samples were 
collected for study immunological response against viral and bacterial antigens and other 
organs for other studies.  
Clinical and histological methods 
Fix/decalcification/OCT embedding of AIA knees for frozen sectioning 
For a good histology analysis and other analysis with confocal microscope is necessary to 
dissect the knee and trim away as much muscle as possible. The knee is put into the Falcon 
tube containing paraformaldehyde (PFA) at 4% in D-PBS 1X (Fixation solution) and store at 
4˚C in a fridge overnight. The day later discard the PFA and wash the knee with D-PBS 1X 
for 4 times. Add 10ml decalcification solution (0.5M EDTA, pH7.4) and seal the tube with 
parafilm and mix on a rotator overnight at 4˚C. The successive step consisted on washing 
the knee with D-PBS 1X and then it is necessary to add 10ml cryoprotectant solution (20% 
(w/v) sucrose, 2% (w/v) PVP in PBS: 40g sucrose in 150 ml of PBS + 4g of PVP in 50 ml of 
= injection site 
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D-PBS 1X) and store at 4˚C in a fridge overnight until the bones sink. Finally, the knee is 
embedded in OCT (CellPath Innovation in cellular Pathology) block and immersed in 
methanol-dry-ice bath to snap freeze. Once frozen, the samples are transfered to -80˚C 
freezer overnight before the section on a cryostat to generate 10μM sections. 
Peptides 
The following peptides were included in the study: 
Peptide Sequence Organism 
BOLF1305-320 wt AAVPVLAFDAA-L-LLE EBV 
BOLF1305-320 Cit AAVPVLAFDAA-{Cit}-L-{Cit}-LLE EBV 
MAP_402718-32 wt AVVPVLAYAAA-LLL MAP 
MAP_402718-32 Cit AVVPVLAYAAA-{Cit}-LLL MAP 
IRF5424-434 wt VVPVAA-LLLE Human 
IRF5424-434 Cit VVPVAA-{Cit}-LLLE Human 
J0I929_HELPX1–11 MIIGGGVSGCA Helicobacter pylori 
IL-256–70 LTEMLTFKFYMPKKA (Pérol L 2016) 
IL-26–20KK KK-LLSCIALSLALVTNS-KK (Pérol L 2016) 
HERV‐Kenv19–37  VWVPGPTDDRCPAKPEEEG HERV-K 
HERV‐Kenv109–126 RPKGKTCPKEIPKGSKNT HERV-K 
HERV‐Kenv164–186  SGQTQSCPSAQVSPAVDSDLTES HERV-K 
HERV‐K env205–226  EKGISTPRPKIISPVSGPEHPE HERV-K 
  
All peptides were synthesized commercially at > 90% purity (LifeTein, South Plainfield, NJ 
07080, USA). 
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Recombinant protein production and plate preparation 
Recombinant proteins were produced by Professor Bach Horacio (Division of Infectious 
Diseases, Faculty of Medicine, The University of British Columbia, Vancouver, BC V6H 3Z6, 
Canada) according to published protocols. The above proteins were provided thank to 
collaboration by Professor Bach and Professor Sechi. In brief, PtpA was produced in M. 
smegmatis harboring the ptpA gene cloned into the vector pALACE (hygromycin resistance), 
whereas PknG was produced in E. coli harbouring the plasmid pknG-pET-30b (kanamycin 
resistance). Both proteins were purified by affinity chromatography using Ni-NTA resin as 
published (Bach H et al., 2006). Produced proteins were stored at -20oC until used. 
ELISA plates were coated with 50 μg/mL of each antigen in PBS overnight at 4oC. The next 
day, plates were washed with PBS, supplemented with Tween-20 (PBS-T) ×3 and blocked 
with BSA 3% in PBS overnight at 4oC. The concentration of antigen used in this study was 
already determined in previous studies as the concentration necessary to obtain a 
differential change in the readout (Xia A et al., 2014), (Gurung RB et al., 2014), (Bach E et 
al., 2018). The next day, the blocking solution was discarded, and the plates were dried at 
room temperature. Plates were then shipped from Professor Bach Horacio to Italy to perform 
the ELISA. Previous studies performed in Bach laboratory indicated that the shipping of 
dried plates did not affect the antigen conformation (Gurung RB et al., 2014). 
ELISA 
Blood human samples were collected in Vacutainer tubes for separation of serum and 
further screening for Abs against BOLF, IRF5 and MAP by indirect ELISA. 96-well plates 
were coated with the selected peptides dissolved in carbonate/bicarbonate buffer at 10mM 
concentration and incubated overnight at 4°C. The next day the wells were saturated with 
Dr. Bo Marco – “Immune response against Mycobacterium avium subsp. paratuberculosis, 
Epstein-Barr virus, HERV-K and IRF5 in rheumatoid arthritis” – PhD thesis in Life Sciences and 
Biotechnologies – University of Sassari, Italy 
101 
 
200μl of blocking solution (1xPBS + 0.05% Tween20 containing 5% skim milk) for 1 h at 
room temperature. Afterwards the plates were washed twice times with 200μl PBS-Tween 
20, diluted sera (1:100) were added in duplicate and incubated for 2 h. The plates were 
subjected to 5 washes with 200μl PBS-Tween with subsequent addition of the alkaline 
phosphatase-conjugated goat anti-human IgG polyclonal Abs at a dilution of 1:1000 and left 
to incubate for 1 h at room temperature. Finally, upon another five washes with 200μl PBS-
Tween 20, para-nitrophenyl phosphate substrate solution was added to each well and the 
plates were incubated at room temperature in the dark for 10 min. The optical density (OD) 
was read at a wavelength of 405 nm using SpectraMax Plus 384 microplate reader 
(Molecular Devices, Sunnyvale, CA). Data was normalized to a positive control serum 
included in all experiments, the reactivity of which was fixed to 1.0 arbitrary units (AU)/ml. 
Competitive inhibition assay 
Sera of two RA patients diluted 1:100 in PBS were pre-incubated for 2h at room temperature 
with MAP_4027, BOLF1 or IRF5 peptide at saturating concentrations of 5μg/ml, 10μg/ml or 
50μg/ml for each epitope. The same samples without peptide were treated accordingly as 
references of seroreactivity. An ELISA was then performed on a plate coated with IRF5 
peptide following the protocol described in the previous section. 
Quantification of lipoproteins in serum samples 
3 mL of peripheral blood were drawn in serum Vacutainer tubes from MS, T1D and RA 
subjects. Blood was centrifuged at 1500 rpm to separate serum for further quantifications of 
HDL (high-density lipoprotein), LDL (low-density lipoproteins), VLDL (very-low density 
lipoproteins) and total cholesterol (TC). Serum was aliquoted and conserved at -20°C for 
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short-term storage (<5 months) and at -80°C for long-term storage (>5 months). The 
quantification was performed using HDL and LDL/VLDL Quantification kit (Sigma-Aldrich). 
Statistical analysis 
The results were expressed as a mean of three separate experiments and the statistical 
significance of the data was determined using Graphpad Prism 6.0 and 8.0 software (San 
Diego, CA, USA). Continuous data are expressed as median (IQR) and comparison was 
made using Mann-Whitney U test. Comparison of positivity to the assessed peptides 
between RA patients and HCs was performed through Fisher’s exact test with both Tukey’s 
and Yate’s corrections. The significance of differences between the OD values of RA, SLE, 
SSc, SSj and HCs groups were determined using ANOVA test with multiple comparisons. 
The same test was employed to assess Abs variations between treatment conditions in 
mice. The cut-off for positivity was established based on the receiver operating characteristic 
(ROC) curve at ≥90% specificity and the corresponding sensitivity. Correlation analysis 
between Abs and RA features, RA activity (DAS-28), systemic inflammation (ESR, CRP) 
and type of immunosuppressive treatment was explored by bivariate correlation analysis, 
univariate and multivariate regression analysis. Probability values lower than 0.05 were 
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